Index

boxes, figures, notes, and tables are indicated by b, f, n, and t following the page number.

Abortion, 499, 510, 1077–1078, 1078t
  Down syndrome and, 942–945, 944t, 948
  illegal and unsafe, 1078
  integration into contraception programs, 1085
  postabortion care, 512–513
Abuja Declaration on HIV/AIDS, Tuberculosis, and Other Related Infectious Diseases, 229
Accountability of Health Provider Organizations, 188
Accreditation
  hospitals, 1223–1224, 1224f, 1226, 1296
  traditional or alternative medicine, 1287
Acne, 708
ACT. See artemisinin combination therapy
Acupuncture, 975, 1282, 1285, 1288
Acute Management, Defined, 59
Acute Myocardial Infarction (AMI), 646, 650–651, 653–654
See also Cardiovascular Disease (CVD)
Acute Pharyngitis in Children, 483–484
Acute Renal Failure, 698
See also Kidney and Urinary System Diseases
Acute Respiratory Infections. See Respiratory Diseases of Adults; Respiratory Diseases of Children
Addiction. See Alcohol Use and Control; Drug Dependence; Tobacco Use and Control
ADHD (Attention Deficit Hyperactivity Disorder), 935b
Adolescents and Young Adults, 1109–1125
  alcohol use by, 1111
  burden of disease and, 1109–1112, 1110t
  cannabis and, 918–919
  clinical health services for, 1116
  contraception and, 1112
  cost-benefit analysis and, 1117–1120
  costs and cost-effectiveness of interventions, 1117, 1118–1119t
  DALYs and, 1109–1111, 1110t
  deworming and, 1116
  drug use by, 1111
  economic benefits of interventions, 1117, 1120t
  health challenges of, 1109
  health risk behaviors of, 1111–1112
  improving health systems to meet needs of, 1122
  injuries and, 1111
  interventions, 1114–1117
  lessons learned, 1120–1122
  mass media as influential on, 1116
  mental disorders and, 621, 1111
  nutrition and, 1111–1112, 1116
  poverty as factor in health of, 1112
  principles of health programming for, 1121
  promising but not proven interventions, 1116–1117
  research and development agenda, 1122–1123
  scaling up of programs for, 1121
  sexual and reproductive behaviors of, 1112, 1113t, 1114–1116
  sexually transmitted infections and, 1112
  smoking and, 875, 1111, 1116
  social marketing and, 1116
  in workplace, 1116
  youth development programs, 1116
Advertising
  See also Social Marketing
  alcohol products, 894
  food marketing aimed at children, 842
  tobacco products, 876
Afghanistan
  leishmaniasis in, 453
  as opium producer, 908
Aflatoxin, 573–574
Africa
  See also specific countries and regions
  Abortions in, 1078
  African Trypanosomiasis in, 456
  asthma in, 686
  burn-related injuries in, 741
  cleft lip and palate in, 731
  community-based health in, 1070–1071
  contraceptive use in, 1082, 1086
  coronary artery disease in, 833
  dental treatment in, 729
  development assistance for health to, 245
  diarrheal diseases in, 778
  epilepsy in, 630
  excreta disposal in, 779, 780
  family planning in, 1079
  hemoglobinopathies in, 668, 676–677, 678
  hepatitis B in, 396
  HIV and TB in, 299
  accountability of health provider organizations, 188
  accreditations
  hospitals, 1223–1224, 1224f, 1226, 1296
  traditional or alternative medicine, 1287
  acne, 708
  ACT. See artemisinin combination therapy
  acupuncture, 975, 1282, 1285, 1288
  acute management, defined, 59
  acute myocardial infarction (AMI), 646, 650–651, 653–654
  See also Cardiovascular Disease (CVD)
  acute pharyngitis in children, 483–484
  acute renal failure, 698
  See also kidney and urinary system diseases
  acute respiratory infections. See respiratory diseases of adults; respiratory diseases of children
  addiction. See alcohol use and control; drug dependence; tobacco use and control
  ADHD (Attention Deficit Hyperactivity Disorder), 935b
  adolescents and young adults, 1109–1125
  alcohol use by, 1111
  burden of disease and, 1109–1112, 1110t
  cannabis and, 918–919
  clinical health services for, 1116
  contraception and, 1112
  cost-benefit analysis and, 1117–1120
  costs and cost-effectiveness of interventions, 1117, 1118–1119t
  DALYs and, 1109–1111, 1110t
  deworming and, 1116
  drug use by, 1111
  economic benefits of interventions, 1117, 1120t
  health challenges of, 1109
  health risk behaviors of, 1111–1112
  improving health systems to meet needs of, 1122
  injuries and, 1111
  interventions, 1114–1117
  lessons learned, 1120–1122
  mass media as influential on, 1116
  mental disorders and, 621, 1111
  nutrition and, 1111–1112, 1116
  poverty as factor in health of, 1112
  principles of health programming for, 1121
  promising but not proven interventions, 1116–1117
  research and development agenda, 1122–1123
  scaling up of programs for, 1121
  sexual and reproductive behaviors of, 1112, 1113t, 1114–1116
  sexually transmitted infections and, 1112
  smoking and, 875, 1111, 1116
  social marketing and, 1116
  in workplace, 1116
  youth development programs, 1116
  advertising
  See also Social Marketing
  alcohol products, 894
  food marketing aimed at children, 842
  tobacco products, 876
  Afghanistan
  leishmaniasis in, 453
  as opium producer, 908
  aflatoxin, 573–574

1357
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) (Agreement on Trade-Related Aspects of Intellectual Property Rights), 190, 220

Agreement on Trade-Related Aspects of Intellectual Property Rights. See TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights)

Agreement on Trade-Related Aspects of Intellectual Property Rights. See TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights)

Agreements on Trade-Related Aspects of Intellectual Property Rights. See TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights)

Agreements on Trade-Related Aspects of Intellectual Property Rights. See TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights)

AIDS. See HIV/AIDS

AIDSVAX, 360b

air and water pollution, 817–832

See also indoor air pollution

air pollutants, 818–820

cases and burden of, 817–822

costs and cost-effectiveness of interventions, 825–827, 826t

daughter air pollution, 825–826

costs and cost-effectiveness of interventions, 825, 827t

dissatisfaction to air pollutants, 819

dissatisfaction to chemical water pollution, 822

health impacts

air pollution, 819–820

water pollution, 822

industrial sectors contributing to, 818, 819t, 821

interventions, 823–824, 823f

air pollution, 823–824, 824b

water pollution, 824

lessons learned

air pollution, 828–829

water pollution, 829

research and development agenda, 829–830

sources of air pollution, 818–819

sources of chemical water pollution, 820–822

water pollutants, 820–822

albinism, 717–718

alcohol use and control, 887–906

discussion as clinical disorder, 887–888

adolescents and, 1111

advertising bans, 894

beneficial effects of moderate alcohol use, 887

costs and cost-effectiveness of interventions, 49, 896–899, 898t

drowning and, 741

drunk driving and, 739–740, 893, 894t, 896–899, 897t

drowning and, 739–740, 893, 894t, 901–902

economic benefits of interventions, 899–900

epidemiology of, 887–890, 888f

fetal alcohol syndrome, 936b

high-risk drinking

burden of disease related to, 890–892, 891t

DALYs attributable to, 892t

epidemiology of, 888–889, 899t

interventions for reducing, 892–896

relationship to alcohol use disorders, 889

interventions for reducing, 892–896

relationship to alcohol use disorders, 889

interpersonal violence and, 760

interventions

brief interventions, 894, 902

population-level effects and costs, 896–899, 897t

self-help, 911

kidney disease and, 699

lessons learned, 900–902

liver cancer and, 573

musculoskeletal disorders and, 966

relationship between alcohol use and disease categories, 889–890

research and development agenda, 902–903

sales hours and places of purchase, regulation of, 893–894, 900–901

social determinants of exposure and risk, 890

taxation to discourage use, 218, 893, 895t, 900

Alcoholics Anonymous, 911

alfacalcidol, 972

allergies and homeopathy, 1288

Alma Ata Declaration on Primary Health Care (1978), 88, 1193

alternative medicine. See complementary and alternative medicine (CAM)

Alzheimer’s disease (AD) and other dementias, 124, 131, 627–629

See also neurological disorders

burden of, 628, 629t

cost-effectiveness of interventions in developing countries, 637

interventions, 628–629

multi-infarct dementia, 628, 629

personal interventions, 629

population-based interventions, 628–629

prevalence and incidence rate, 628

recommendations, 640

research and development agenda, 640, 641

risk and protective factors and survivorship, 628

women and, 201, 205–206

ambulances, 1267–1271, 1269t, 1270t

ambulatory care. See primary care

American Academy of Pediatrics recommendation on television watching, 835

American Heart Association, 651, 658

American Psychiatric Association, 908

American trypanosomiasis. See Chagas disease

AMI. See acute myocardial infarction

amphetamine. See drug dependence

anemia

in adolescents, 1111

in AIDS patients, 359–360

in children, 553–554, 1094

costs and cost-effectiveness of interventions, 561

developmental delays and, 562

helminth infections and, 467–468, 471, 553

interventions, 558

lack of data on interventions for, 563–564

in pregnant women with malaria, 420

in school-age children, 1094

ankylosing spondylitis, 976

anthrax, 107
antibiotics, indiscriminate use of, 122, 1340
See also drug resistance in animals, 1032–1033, 1041 in humans, 314, 378, 1031–1032
antiretroviral drugs (ART)
anxiety disorders, 611–613
See also mental disorders
cost-effectiveness methods and results, 613–619, 614–618 generalized anxiety disorder, 611 interventions for panic disorder, 612–613 natural history and course, 612 obsessive-compulsive disorders, 612 phobias, 612 posttraumatic stress disorder (PTSD), 605, 610, 621 social anxiety disorder, 611
APOC. See African Programme for Onchocerciasis “appropriate science” for developing world, 109–111
Argentina
arsenic contamination of water in, 821 Chagas disease in, 438, 442 fluoridation of water in, 725 kidney and urinary system diseases in, 703
array technology, 128 arsenic contamination of water, 821, 822, 822b
ART. See antiretroviral drugs artemisinin, use of, 111, 1288 artemisinin combination therapy (ACT), 419, 420–421, 423, 424, 425, 427, 1043 arthritis. See musculoskeletal disorders asbestos. See occupational lung diseases ascariasis
excreta disposal and, 783–784 water supply and, 779
Asia
See also specific countries and regions
abortions in, 1078 asthma in, 686 avian influenza in, 682–683b burn-related injuries in, 741 contraceptive use in, 1076, 1086 dengue in, 461 diarrheal diseases in, 373, 778
Asia
drug dependence in, 908, 916 excreta disposal in, 780 hepatitis B in, 396 kidney and urinary system diseases and, 697 leprosy in, 445 malaria in, 413, 417, 421 rheumatic heart disease in, 647 road traffic injuries in, 740 water supply in, 772, 773–774, 774, 776
Asian Development Bank, 1070 Asian-Pacific International Molecular Biology Network, 133 aspirin cancer and, 574 as inexpensive intervention for CVD, 109, 123f asthma. See chronic obstructive pulmonary disease (COPD) and asthma attention deficit hyperactivity disorder (ADHD), 935b
Australia
COPD and asthma in, 686 dengue in, 452 detoxification methods in, 912 ecstasy (MDMA) use in, 924 heroin use in, 908, 909 illicit drug use in, 909, 922 interpersonal violence in, 763 kidney and urinary system diseases in, 700 skin diseases in, 708, 710 tobacco taxes in, 882 traditional medicine in, 1289 autism, 935b avian influenza threat, 112b, 117, 682–683b, 1005–1006 ayurveda, 1286 bacillus Calmette-Guérin (BCG), 40, 121, 292, 389, 441, 1325 back pain. See musculoskeletal disorders bacterial skin infections, 708, 709, 710–713, 712–713t Bamako Initiative, 227 Bangladesh
arsenic contamination of water in, 821, 822b child mortality of under age five in, 246 community-based programs in, 1067 contraceptive use in, 1083 contracting for health care services in, 188, 1320 development assistance and health policy, 248b diarrheal diseases in, 170, 176, 372, 374 drowning in, 741 excreta disposal in, 780, 782 family planning program in, 167 helminth disease control in, 784 hospitals in, 1220b, 1257b IMCI program in, 1180–1181, 1187 interpersonal violence in, 756, 757 leishmaniasis in, 452 leprosy in, 441 medical workers in, 1312 neonatal deaths in, 531, 533, 1079 nutrition investment in, 248b respiratory diseases of children in, 492 road traffic injuries in, 746 TB in, 291, 295 tidal wave in, 1149 BCG. See bacillus Calmette-Guérin behavioral change interventions successful programs, 175–177 Belarus cardiovascular disease in, 649, 649t Belize interpersonal violence in, 766 Bellagio Study Group on Child Survival, 539, 541, 1196, 1202 Belmont Report of National Commission for the Protection of Human Subjects, 267 benign prostatic hypertrophy, 698 See also kidney and urinary system diseases Benin excreta disposal in, 780 hemoglobinopathies in, 675 road traffic injuries in, 749b Bernard, Claude, 119 Better Health in Africa (World Bank), 1194 Bhopal catastrophe (India 1984), 819, 819b, 1133, 1149 bicycles. See transportation Bill & Melinda Gates Foundation AIDS prevention efforts and, 254 development assistance for health from, 165, 240n5, 243, 244–245, 244t, 397 disease control priorities and, 111, 115 Diseases of the Most Impoverished initiative and, 378 economic issues for future medical research and, 134 food fortification efforts and, 254 funding commitment for disease control in developing countries, 147 MCE and, 1190 MDGs and, 182 polio eradication efforts and, 24, 254b, 1171 stimulating growth of public-private partnerships, 147
biologic terrorism
surveillance for, 998, 1008
biologically based practices, 1282
See also complementary and alternative medicine (CAM)
biomedical research priorities, 126, 132
bipolar disorder, 608–610
See also mental disorders
costs and cost-effectiveness of interventions, 47, 613–619, 614–618t
epidemiology and burden, 609
genomics and, 131
interventions, 609–610
natural history and course, 609
policy and service implications, 619–621
bird flu. See avian influenza threat
blackfly control, 178, 435
blindness,
178, 435
Chagas disease in, 436, 438–439
river blindness. See Onchocerciasis
blood pressure. See cardiovascular disease (CVD)
blood-related disorders. See hemoglobinopathies
blood safety measures, 346
blood transfusions
Chagas disease and, 434, 438–439
HIV/AIDS and, 346–347
Bolivia
Chagas disease in, 436, 438, 442
newborn project in, 535
Bone and Joint Decade (2000–10), 963, 978
bone marrow transplantation. See hemoglobinopathies
Botswana
African trypanosomiasis in, 458
HIV/AIDS in, 349, 360b
brain drain of medical personnel, 94, 95b, 1309–1310
Brazil
alcohol consumption regulation in, 900–901
breast cancer management in, 205
cardiopulmonary disease in, 650, 659
cervical cancer screening in, 576, 577t
Chagas disease in, 436, 438, 442
combination of high blood pressure, cholesterol, and obesity in, 853–854
dengue in, 461
diarrheal diseases in, 374, 375, 376, 378, 778
excreta disposal in, 783
fluoridation of water in, 725
health knowledge, dissemination to mothers, 187
HIV/AIDS in, 13, 106
IMCI program in, 1181, 1183, 1185b, 1186
leishmaniasis in, 452
leprosy in, 437
lifestyle changes in, 839b, 841b
malaria in, 418
Multi-Country Evaluation of IMCI Effectiveness, Cost, and Impact (MCE) in, 1183
occupational health in, 1140
physical activity initiative in, 841b
road traffic injuries in, 744, 745–746, 900–901
sexually transmitted infections in, 323
skin diseases in, 715
smallpox in, 1163
surveillance project in, 1021
transportation policy in, 839b
water pollution in, 829
breast cancer, 205
age-specific incidence of, 582f
chemotherapy for, 268, 580–581
mind-body interventions and, 1288–1289
radiation for, 581
rates of, 570
screening for, 577–579, 578t, 579t, 580t
tamoxifen and, 574
treatment interventions for, 580–581
breastfeeding
community health and nutrition programs, 1058
diarrheal disease prevention due to, 375–376, 379
duration of, 555
infant mortality and, 539
programs to promote, 559
supplemental or substitute feeding, 345, 375–376, 555, 557b, 1058
transmission of HIV and, 334, 336, 375
bronchiolitis, 485
bronchitis. See chronic obstructive pulmonary disease (COPD) and asthma
Brunei
fluoridation of water in, 725
Bulgaria
milk fluoridation in, 726
burden of disease, 105–106
See also specific diseases and categories of diseases (e.g., infectious diseases, tropical diseases)
broad patterns of (by region), 105t, 1335
children under age five, 105–106
estimates for different diseases and injuries, 28–32
as factor in cost-effectiveness analysis, 272–273
leading causes of (by region), 105t
in low- and middle-income countries, 31t
purpose of measures of, 29–32
shift from infectious to noncommunicable diseases as major causes, 1331, 1333
women’s excess burden, 196, 198–199, 199t, 200t, 201t
Burkina Faso
African trypanosomiasis in, 458
drug policy in, 1346
health care worker safety for immunizations and injections in, 1132
hygiene promotion in, 785
malaria in, 421
sexually transmitted infections in, 325
burn-related injuries. See unintentional injuries
calcitonin, 972
calcium supplementation, 967, 971–972
CAM. See complementary and alternative medicine
Cambodia
avian influenza in, 682b
dengue in, 454
health sector reform in, 1315
IMCI program in, 1186, 1187
medical workers’ New Deal experiment in, 1317–1318, 1319b
oral precancer and cancer in, 730
outsourcing of primary health care services in, 96b
performance-based contracts with NGOs in, 253
refugee populations and surveillance, 1009
sexual risk behaviors in, 312
water pollution in, 829
Cameroon
drug treatment in, 1346
malaria in, 426
sexually transmitted infections in, 323
user fees and improved quality in, 89
Canada

cigarette smoking, 875, 877
development assistance for health from, 244, 254
fluoridation of water in, 725
hemoglobinopathies in, 673, 675
illicit drug use costs in, 909
interpersonal violence in, 760, 765
pollution control in, 828
SARS in, 1005
cancer, 569–589
See also specific types
burden of, 107, 569–572, 570f
DALYs lost due to, 570, 571t
burden of, 107, 569–572, 570f
See also specific types
Canada
congestive heart failure, 646
clinical research, 659
congestive heart failure. See congestive heart failure (CHF)
costs and cost-effectiveness of interventions, 47–48, 650–658, 655t, 656t, 657t, 858–863, 861t
demographic changes and, 105
diabetes and, 597
diet contributing to, 652
See also obesity
epidemiology of, 645–649, 648t
equity issues and prevention strategies, 863
folic acid and, 836
glossary, 646b
hypertension
CHF and, 646
control of, 646
IHD and, 646
kidney disease and, 698, 699, 700, 701
as risk factor, 649, 652
strokes and, 633, 634, 641
hypertension in combination with cholesterol and obesity, 851–868
burden of, 852–854, 853f, 853t
cost-effectiveness of interventions, 858–863, 861t
economic benefits of interventions, 864
effectiveness of interventions, 855–858
epidemiology of, 851–852, 852f
equity issues, 863
financial burden of, 853–854
interventions, 854–858
personal interventions, 856–858
pharmacological interventions, 856–858, 859t
population-based interventions, 855–856, 859
research and development agenda, 864–865
surgical interventions, 856–858
surveillance and, 1009
ischemic heart disease. See ischemic heart disease (IHD)
lifestyle changes in response to, 652
linking costs and effectiveness in developing countries, 653–656, 655t, 656t
in high-income countries, 656–658, 657t
long-term management of, 651–652
invasive interventions, 651
nonpharmacological interventions, 652
pharmacological interventions, 651–652
personal interventions for, 48, 856–858
pharmacological interventions, 15–16, 650–654, 656, 658, 856–858, 859t, 860–863, 862t, 863t
population-based primary prevention of, 47–48
predominant diseases, 645–649
primary prevention, 658
regional burdens, 649–650
research and development agenda, 658–659, 864–865
rheumatic heart disease (RHD), 647, 656
burden of, 650
cost-effectiveness of interventions, 653, 656, 657t, 658
epidemiological transition and, 647, 648t
strokes and, 634
risk factors, 649, 851–862, 854t
social and economic impact of, 650, 864
strokes and, 634, 645–646, 646, 647, 648t, 649–650, 657t, 658
types of inexpensive interventions for, 109, 123f
women and, 201
Caribbean. See Latin America and Caribbean
carter center, 167
cash-transfer programs to increase school enrollment, 1101
cataracts. See blindness
cattle
African trypanosomiasis and, 458
CBHI. See community-based health insurance
CDC. See U.S. Centers for Disease Control and Prevention
cell theory, 119
census data, 1020
Center for Global Development’s Global Health Policy Research Network, 165
Central America. See Latin America and Caribbean
Central Asia
cardiovascular disease in, 649, 654, 655t, 656t
contraception demand in, 1076
diarrheal diseases in, 378
mental disorders in, 618, 619
proposed guidelines for HIV/AIDS in, 348–349
road traffic injuries in, 746
strokes in, 634
TB, spread of, 291
vaccine-preventable diseases in, 394, 399, 400, 402, 408
cerebral palsy, 947, 948

cerebrovascular disease. See Alzheimer’s disease (AD) and other dementias; stroke

cervical cancer

age-specific incidence of, 582f
HBV vaccine and, 573
HPV, association with, 569
mortality rates and, 570
radiation for, 581
screening for, 203–205, 575–577, 577t

treatment interventions for, 312, 581

Chagas disease, 433–434

burden of, 436
cardiovascular disease and, 650
costs and cost-effectiveness of interventions, 45–46, 442
treatment interventions and effectiveness of, 438–439
research priorities, 446

Southern Cone countries initiative on, 167, 170, 177, 438

chemotherapy

for cancer, 268, 574, 580–581, 583
for schistosomiasis, 474, 479
for TB, 1045

Chernobyl nuclear disaster (1986), 819, 1133

CHE. See congestive heart failure

child abuse, 756, 758, 765
See also interpersonal violence

Child Health Epidemiology Reference Group, 533

child mortality rates

under age 5 mortality, 11–13, 12f
diarrheal disease and, 374
interventions for, 11–13
malaria and, 416t
malnutrition and, 552, 552t
MDGs for, 7, 11
rate of progress in reducing, 12f, 246
infant and neonatal mortality, 4b, 505–508, 507t, 531–549
achieving optimal newborn care within system constraints, 544–546
advocating for newborn health, 544
cost of scaling up universal neonatal packages, 541–543, 542t, 544b
delays in access to care and, 534
direct causes of, 533–534
emergency care and, 540–541
esential newborn care and, 535–539
family-community care and, 535
in first week after birth, 532
income level of countries and, 532, 533f, 533t
indirect causes of, 534
interventions for, 4b, 43–44, 535–541, 536–538t
lessons learned, 543–547
low birthweight and, 534, 540
MDGs on, 7, 531, 534, 547–548
monitoring of coverage and measuring for cost-effectiveness, 546–547
neural tube defects and, 939
poverty and, 534
research priorities, 547
resuscitation program and, 539–540, 539b, 545
systematic scaling-up of newborn care, 546
time trends and, 532–533, 532f
malaria and, 414, 416t, 417, 418, 421, 423, 556
child sexual abuse, 764
See also interpersonal violence

Child Survival and Development Projects (World Bank), 1068

childbirth conditions

See also maternal conditions
access to skilled attendance, 44, 512, 547b
birth preparedness, 511
components of comprehensive safe motherhood strategy, 508–509, 509b
cost-effective interventions, 44
fetal monitoring and, 948
male involvement, 511
maternal death. See maternal mortality
midwives, role of, 174, 511
neonatal death. See child mortality rates
preterm birth, 534, 547
prevention of, 947–948
retinopathy of prematurity, 954–955
quality of evidence on, 509–510, 512
risks associated with, 1078–1079
sexually transmitted infections of mother and, 315
strokes and, 634
technological improvements in, 131

childhood health, 10–13
See also specific diseases and conditions under age five. See childhood illnesses of children under age 5

community health and nutrition programs. See community health and nutrition programs (CHNPs)
dental health. See dental caries
helminth infections and, 471, 473, 474
improved quality of treatment for children with childhood diseases, 1303–1304
integrated services. See integrated management of childhood illness (IMCI)
interpersonal violence. See interpersonal violence
learning disabilities. See learning and developmental disabilities (LDDs)
nutrition. See stunting, wasting, and micronutrient deficiency disorders
mental disorders and, 621
out-of-school children and youth, 1098, 1121–1122
perinatal conditions, 499–529
See also perinatal conditions
research priority of, 126
respiratory disease. See respiratory diseases of children
rheumatic heart disease and, 647

school-based health. See school health programs
stunting, wasting, and micronutrient deficiency disorders, 551–567
TB and, 293
Tinea capitis, 714–715, 716t, 718, 719t
unintentional injuries. See unintentional injuries

childhood illnesses of children under age 5

burden of, 105–106
deaths. See child mortality rates
interventions, 43–45
malnutrition and, 552, 553t

Chile

arsenic contamination of water in, 821
Chagas disease in, 436, 438, 442
combination of high blood pressure, cholesterol, and obesity in, 856
fluoridation of water in, 725
food fortification in, 558
Hib disease prevention in, 167, 172
interpersonal violence in, 760
life expectancy, increases in, 3
noncommunicable diseases and causes of death in, 6, 7f
occupational health in, 1133
pain control in, 987b
public health improvements in, 3
respiratory diseases of adults in, 691
universal coverage approach of, 237

China

abortions in, 1078
arsenic contamination of water in, 821
artemisinin use in, 1288
asbestos exposure in, 1128
burn-related injuries in, 741
cardiovascular disease in, 647, 649, 650, 658, 659
combination of high blood pressure, cholesterol, and obesity in, 853–854, 856
contraceptive use in, 1080
dengue in, 452
diabetes in, 593
diarrheal diseases in, 374, 377
drug addiction in, 908, 916
fall-related injuries in, 748–749
folic acid deficiency in, 836
food manufacture in, 845
food taxes in, 219
hemoglobinopathies in, 668, 670
hypertension in, 835
incentive pay to doctors in, 94–95, 95b, 170
indoor air quality and energy programs in, 190, 795, 809, 810b
influenza in, 684
kidney and urinary system diseases in, 702, 703
lung cancer in, 795
lymphatic filariasis in, 436
malaria in, 421, 425
mental disorders in, 620
milk fluoridation in, 726
neonatal deaths in, 531
neonatal resuscitation program in, 539b
neurological disorders in, 628
oral and craniofacial diseases and disorders in, 723
oral health and education program in, 726
road traffic injuries in, 740, 747, 839
rotavirus vaccine in, 377
salt iodination program in, 168, 173
SARS in, 997, 1005
school-based physical activity in, 838
stomach cancer in, 573
strokes in, 633
TB control program in, 36b, 94–95, 168–169, 174, 247
tobacco use in, 871, 1128
transportation choices in, 839–840
vital events registration in, 1021
water pollution in, 829
women in, 195
chiropractic medicine, 1282, 1286, 1288
chlamydia, 203, 312, 314–315, 316
See also sexually transmitted infections (STIs)
chlorination, 821
chloroquine, 414, 418, 420f, 423, 1035f, 1043f, 1327
CHNPs. See community health and nutrition programs
cholera, 120, 377, 379, 774, 777, 778
cholesterol levels
in combination with high blood pressure and obesity, 851–868
See also cardiovascular disease (CVD)
CVD and, 15
diabetes and, 598
drugs to control, 857, 1323
modeling of interventions for lifestyle diseases, 844–845
chronic diseases, 833–850
See also specific diseases
advances in treatment of, 123
alcohol use and, 890
burden of, 107, 1333
community-based interventions, 842, 846
cost-effectiveness of interventions, 844–846
diet and lifestyle changes to prevent, 833–836, 847
evidence of effectiveness, 836–837
educational interventions, 837–838
health care providers modifying unhealthy behaviors, 838
interventions, 837–844
recommended priority interventions, 846–848
malnutrition in childhood associated with, 563
medications for, 1331
modeling of likely interventions, 844–846
physical activity interventions, 835, 838, 841b, 842, 846, 847
research and development agenda, 846
surveillance and, 1009–1010
transportation policy and environmental design as intervention, 839–840
worksite interventions, 838, 838b
chronic kidney disease (CKD). See kidney and urinary system diseases
chronic obstructive pulmonary disease (COPD) and asthma, 684–689, 685f, 687t
See also respiratory diseases of adults
air pollution and asthma in children, 820
cigarette smoking. See tobacco use and control
circumcision to protect against sexually transmitted infections, 320, 322, 360b
civil service reform, 96
CKD (chronic kidney disease). See kidney and urinary system diseases
Clean Air Act of 1970 (U.S.), 828, 829t
clean drinking water. See water supply
cleft lip and palate, 731
cclimate
See also global warming
health systems’ efficacy and, 1340
helminth infections and, 470
Clinton Foundation, 359, 1333
cocaine. See drug dependence
cognitive function
cannabis and, 918
malnutrition’s effect on, 562
of school-age children. See school health programs
COHRED. See Council on Health Research for Development
collaboration for research. See research and development
collective efficacy, 1067
Colombia
ambulatory surgery in, 1256
contraception, access to, 1076
interpersonal violence in, 756, 763
stomach cancer in, 573
universal coverage approach of, 237
volcanic eruptions in, 1150
colorectal cancer, 570, 574, 575, 575t, 581, 836
Commission on Health Research in Development, 106
Commission on Macroeconomics and Health (WHO)
on close-to-client services, 521
on constraints of low-income countries to improve health care, 98
on cost-effective analyses, 234, 261
on district hospitals, 1214
on external financing for health, 245
on HIV/AIDS, 9
on mobilizing skills and resources, 134
on primary care interventions, 246, 1194, 1200
on scaling up health coverage, 190
on training to enhance skills of medical workers, 1344
Common Rule of Conduct of U.S. Code of Federal Regulations, 266
communicable diseases. See infectious and communicable diseases
communication for emergency medical services, 1267
community-based health insurance (CBHI), 231, 236
community-based programs and treatment
breastfeeding, programs to promote, 559
central government transfers to local authorities for, 253
community health and nutrition programs, 1053–1074
community-based programs and treatment (Continued)

See also community health and nutrition programs (CHNPs)
decentralizing health functions to, 253 depression treatment, 110
epilepsy treatment for children, 110 HIV/AIDS, 1070–1071
home-based care, 1204 IMCI and, 1178, 1180
infant and neonatal mortality and, 535 learning and developmental disabilities, 946–947
management of health services in, 1343–1344
mental disorders, 608, 613, 615–616t, 615t, 619, 621
neurological disorders, 631, 641
nutrition programs, 559, 561, 842, 846
See also community health and nutrition programs (CHNPs)
onchocerciasis control program, 440 oral health and, 732
physical activity programs, 842, 846
primary care, 1202, 1204
scabies and, 710
skin diseases, 710, 715, 718, 720
Tanzania Essential Health Interventions Program approach to health planning for. See Tanzania Essential Health Intervention Program (TEHIP)
TB, quality of care and treatment of, 295
community clinics and surgery, 1249, 1253–1255, 1253t, 1254t, 1256f
community health and nutrition programs (CHNPs), 1053–1074
breastfeeding and, 1058
community- and facility-based programs, 1056–1057, 1059f, 1060b
complementary feeding of children and, 1058
contextual factors for, 1065–1067, 1065t
cost-effectiveness of, 1068–1070
coverage, targeting, and resource intensity, 1060–1063, 1061–1062t
description of, 1058–1059
effectiveness of, 1054–1056, 1055t
estimated contributions to disease burden, 1054t
future applications of, 1070–1071
growth monitoring, 1058
HIV/AIDS and, 1070–1071
IMCIs and, 1056
immunizations, 1059
impact of, 1067–1068, 1069t
micronutrient fortification, 1059
micronutrient supplementation, 1058–1059
oral rehydration, 1059
organization of, 1064
political commitment and, 1066
prenatal care, 1058
process indicators and, 1067
programmatic factors for, 1060–1064
research and development agenda, 1071–1072
success factors for, 1057–1058
supplementary feeding, 1059
technology and, 1063
underweight children and, 1055, 1056f
women's health and nutrition, 1058
workers in, 1063–1064
community violence, 756
See also interpersonal violence
complementary and alternative medicine (CAM), 1281–1291
See also specific types of treatment (e.g., acupuncture, homeopathy)
ancillary benefits and costs of, 1286 defined, 1281
demography and use of, 1282–1283, 1282t, 1283t
domains of, 1281–1282
economic evidence on use of, 1285–1286
economic factors influencing use of, 1283–1285
efficacy of, 1283, 1284t
epilepsy and, 630
expanding beneficial use of, 1286–1287
lessons learned, 1287–1289
for mental disorders, 620
for neurological disorders, 629, 641
for Parkinson's disease, 632, 640, 641
research and development agenda, 1289
for skin diseases, 715
toxicity of herbal products, 1283
conditionality and development assistance, 247
condoms
See also HIV/AIDS
import taxes not charged on, 220
subsidy programs, 216
Thailand distribution program. See Thailand use as contraceptive, 1080, 1082, 1086
See also contraception
congenital and developmental disorders
cleft lip and palate, 731
hyperthyroidism, 945–946, 949
medical treatment of, 123
oral and craniofacial diseases and disorders, 731
research priority of, 126
congestive heart failure (CHF), 646–647
See also cardiovascular disease (CVD)
cost-effectiveness of interventions, 653
in developing countries, 654, 656
in high-income countries, 656, 657t, 658
Congo, Democratic Republic of
African trypanosomiasis in, 454
Ebola in, 1006
consumer subsidies, 212–218
consumer taxes, 218–220, 219b
textual content
cost-effective interventions, 24–27, 25t, 35–86, 36f
See also specific diseases and conditions
analysis of. See cost-effectiveness analysis
assessing evidence of, 40–50, 41–42f
building health systems, 27, 53–58
communicable diseases, 53
lack of reliable data on, 58
methodology of study, 38–40, 39t
noncommunicable diseases, 53
personal. See personal interventions
policy setting and, 36b
population-based. See population-based interventions
priority setting, 35–38, 37–38b, 271–273
private sector and, 38
quality as determinant of
cost-effectiveness, 50
regional variations, 39
target audiences and, 38
technological progress and, 53
women and, 203–206, 204–205t
cost-effectiveness analysis, 26b, 271–285
aggregation and cost differences in,
263–264
amount of health (by service or intervention) US$1 million will buy, 25t, 284
burden of disease and, 272–273
CER, use of. See cost-effectiveness ratio
costs of producing intervention used in,
261–262
currency units used in, 281
data for, 281–282
defined, 271
discounting in, 262, 278
discrimination against persons with
disabilities, 264–265
estimating effectiveness in health,
277–280
ethical considerations for, 259–260, 272
evaluation of health benefits in,
260–261
evaluation of nonhealth benefits in, 279
fair chances and best outcomes in, 264
improving, 284
modeling in, 281
population impact and, 283–284
quality-adjusted life years in.
See quality-adjusted life years (QALYs)
reasons to develop, 273–277
reliability and uncertainty of, 282–283
resource allocation based on, problems from, 262–265
for South Asia and Sub-Saharan Africa, 50, 51–52t
unit of measurement of health, 278–280
See also DALYs (disability-adjusted life years)
weighting of life years in, 261
cost-effectiveness ratio
average and incremental, use of, 275, 276–277b, 283
defined, 271–272
use of, 272, 282
Costa Rica
child mortality in, 1068
community-based programs in, 1065,
1066, 1067, 1068
diet in, 836
disaster damage to hospitals in, 1156
health sector reform in, 1298
interpersonal violence in, 766
universal coverage approach of, 237
Côte d’Ivoire
African trypanosomiasis in, 459, 460
malaria in, 426
road traffic injuries in, 749b
Council for International Organizations of
Medical Sciences, 266
Council on Health Research for
Development (COHRED), 161, 1297
counterfeit medicines, 1327
craniofacial diseases. See oral and
craniofacial diseases and disorders
criminal enforcement for dependent illicit
opioid use, 911–912
Croatia
cardiovascular disease in, 649, 649t
cross-level services and inputs
district hospitals and, 1215, 1222–1226
Crossing the Quality Chasm (IOM), 1295
Cuba
dengue in, 454, 455, 461
public health improvements in, 88
cure
defined, 59
CVD. See cardiovascular disease
Cyprus
hemoglobinopathies in, 665, 673
malaria in, 421
Czech Republic
cardiovascular disease in, 649
data collection. See information systems
Daubert v. Merrell Dow Pharmaceuticals
(1993), 153
day care at work, 221
DCPP. See Disease Control Priorities Project
defeat. See hearing loss
death. See child mortality; mortality rates;
specific diseases
decentralizing health functions to local
governments, 253
decision making, information for,
1017–1030
See also information systems
Declaration of Helsinki, 266, 267, 268,
269n3
dehydration. See oral rehydration
therapy (ORT)
dementia. See Alzheimer’s disease (AD) and
other dementias
demographic changes of 20th century, 124
Demonstration in Small Industries for
Reducing Wastes Project, 825b
dengue
burden of, 454–455
characteristics and transmission, 451–452
costs and cost-effectiveness of interventions, 459
economic impact of, 455
management and control strategies of, 457
risk factors of, 461
social impact of, 455
vaccine development for, 460–461
dental caries, 723–729, 724t, 725f
common-risk-factors intervention
programs, 731–732, 732t
cost-effectiveness of oral health care,
733–734, 733f
effectiveness of oral health programs, 726,
727–728t, 729
fluoridation and, 168
intervention programs, 725–726
oral health education and promotion pro-
grams, 726
research and future action, 733
treatment of, 729
depression
See also major depressive disorders
burden of, 107, 1334
community-based treatment of, 110
costs and cost-effectiveness of interventions, 47
women and, 107, 196, 201, 202, 206
detoxification. See drug dependence
developed countries. See high-income
countries
developing countries. See low-income countries

development assistance and health policy, 22–25, 28, 243–257

See also Millennium Development Goals (MDGs)
absorptive capacity of countries and, 232–233, 232t
aid effectiveness and, 233, 250–256
reaching local communities, 255–256
budget support and, 250–251
central government transfers to local authorities, 253
conditionality and, 247
donor disbursements to national governments, 253
fungibility vs. earmarking of funding, 247–249
harmonizing procedures in, 249, 251
lessons learned, 246–250
performance-based financing, 251–253
policy environment and, 246–247
private sector and, 253–255
pooling of donor funding, 251
performance-based financing, 251–253
lessons learned, 246–250
harmonizing procedures in, 249, 251
transaction costs of, 249
sources and amounts, 243–244, 244t
transaction costs of, 249–250, 250t
developmental disabilities, 933–951
See also learning and developmental disabilities (LDDs)
developmental disorders at birth.
See congenital and developmental disorders
deworming. See helmhith infections
Diabcare-Asia project, 599
diabetes, 591–603
combination of hypertension, cholesterol, and obesity and, 851
cost-effectiveness of interventions, 594t, 595–599, 600–602, 601t
estimating in developing countries, 595, 596t
ranking implementation priorities, 595–598
death and disability rate of, 591–592
diet contributing to, 836
economic burden of, 592–593
education on, 598
epidemiological and economic research, 600
epidemiological transitions and, 124
estimated prevalence of, 591, 592t
foot problems and, 597
health systems and operational research, 600
increasing burden of, 107, 591–592, 600, 1333
insulin resistance syndrome and, 834b
interventions, 593–595
kidney disease and, 695, 698, 699, 700, 702
lessons learned, 599–600
lifestyle changes in response to, 593
low birthweight and, 121
management of, 594–595
nature and distribution of, 591–593
periodontal disease and, 729–730
prevention, 599, 600
quality of treatment and care, 599–600
research and development agenda, 600
risk factors for, 593
screening for, 594, 598
self-management of, 598
stokes and, 633–634
type 1 diabetes, 593
type 2 diabetes, 593
Diabetes Prevention Program, 593
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IVTR)
(American Psychiatric Association), 607, 908
diagnoses, development of, 144–146, 145, 145t
diaphragms. See contraception
diarrheal diseases, 371–387
See also oral rehydration therapy (ORT)
bleeding diarrhea
diagnosis of, 372
management of, 378
breastfeeding preventing, 375–376, 379
burden of, 373–375, 373f
case management of, 378
cholera immunization and, 377
complementary feeding practices
and, 376
cost-effectiveness of interventions, 378–383, 380–382t, 383f, 383t
drug therapy for, 378
environment and, 373
hand washing to prevent. See hand washing as intervention
interventions, 45, 375–377
laboratory diagnosis of, 372
long-term consequences of, 374–375
malnutrition and, 372
measles immunization and, 377
mortality rate and, 372, 374, 374f
oral rehydration therapy and. See oral rehydration therapy (ORT)
personal and domestic hygiene, 377
poverty and, 373
public health significance of, 373, 373f, 374–375, 374f
research and development agenda, 383–384
rotavirus immunization, 376–377
successful programs in combating, 167, 176, 375–377, 1303–1304
syndromic diagnosis of, 372
transmission of, 371–372
water and sanitary facilities and, 187, 189–190, 377, 776, 777, 777t, 782, 785, 786–791, 786t, 787f, 789t, 790t, 791t
See also sanitation improvements; water supply
zinc supplementation and, 378
diét. See nutrition
Difference Principle, 262
diphtheria, pertussis, tetanus
See also Expanded Program on Immunization (EPI);
control of, 394–395
neonatal deaths caused by tetanus, 533, 534
vaccine, combined with Hib
vaccine, 405b
vaccine for, 121, 389, 1325
directly observed therapy short course (DOTS), 36b, 110, 170, 174, 289, 293–294, 293–295, 303–304, 1041, 1044–1045
agenda for action, 1045–1046
disabled persons
discrimination against, 264–265
disaster relief
cash assistance, 1157–1158
coordination of humanitarian effort, 1154
costs and cost-effectiveness of interventions, 1156–1158
disease prevention and control, 1157
donations and supplies following, 1154, 1157
emergency preparedness of health sector, 1155, 1158
field hospitals for, 1157
hospital damage and, 1155–1156
in-kind donations, 1157
lessons learned, 1159, 1161
mobilization of resources, 1158–1159
preparedness funding, 1158
prevention and mitigation, 1155–1156, 1158
funding for, 1159
reconstruction funding, 1159
disasters, 1147–1162
See also disaster relief
age and, 1149
classification of, 1147
climatic disasters, 1151
communicable diseases and, 1151, 1154
earthquakes, 1149–1150, 1150t
economic valuation of, 1151–1152
environmental health and, 1154
gender and, 1149
hazards, defined, 1148
health and economic losses from, 1148, 1148f
hospitals and health installations, damage to, 1153
hurricanes, 1151
interventions, 1153–1156
long-term impact, 1151–1153, 1152t
mass casualties, treatment of, 1154
poverty and, 1149
resilience, defined, 1148
risk
defined, 1148
geographic distribution of, 1148–1149
short-term health burden of, 1149–1151
surveillance in, 1008, 1154
terminology for, 1147–1148
tsunamis, 1150
volcanic eruptions, 1150
vulnerability
defined, 1148
factors affecting, 1149
water and sewage systems, damage to, 1153, 1156
discount rate, 262, 278
discrimination
against HIV positive individuals, 109
against persons with disabilities, 264–265
social exclusion and public health, 1072n1
Disease Control Priorities in Developing Countries (DCP) (Jamison et al., 1993)
burden of disease estimates, 279
estimates of deaths by causes, 28
intervention focus of, 16
Disease Control Priorities Project (DCPP)
death estimates for, 11b
on diarrheal diseases, 378–379
focus on most cost-effective interventions for developing countries, 165
on suicides, 607
on tuberculosis, 295–296
district hospitals, 1211–1228
central financing of, 1220–1221
changing disease spectrum, implications of, 1226
clinical management of, 1223
clinical services provided by, 1214–1215
cost-effectiveness of services, 1216, 1219, 1220t
costs of care in, 1218–1219, 1218t
cross-cutting services and, 1215
1222–1226
defined, 1212
demand for services, 1221–1222
economics of, 1216–1219
ecosystems of scale and, 1213, 1213f
efficiency and, 1213, 1217–1218, 1219t, 1224–1225
equity issues and, 1214
factors influencing performance of, 1219–1222
framework for delivery of services by, 1212f
health information systems and, 1216
hospital-acquired diseases in, 1224
human resources and, 1223
integration with other local health-related services, 1215
levels of care, 1217
national level and costs, 1217
private sector and, 1217
quality improvements and accreditation of, 1223–1224, 1224f, 1226
research and development agenda, 1226
services provided by, 1214
supervision and, 1216
supply of services, 1222
surgery and, 5b, 27, 1249, 1253–1255, 1253t, 1254t, 1256f
technology, information, and integration in, 1223, 1226
training and, 1215–1216
DNA markers, study of. See genomics
Doctors without Borders’ Drugs for Neglected Diseases, 1323
Doha Declaration, 151
domestic violence, 48–49, 202, 756, 760
See also interpersonal violence
Dominican Republic
contraceptive use in, 1081
sexual risk behaviors in, 312
DOTS. See directly observed therapy short course
Down syndrome, 941–945, 944t
dracunoucliasis. See guinea worm eradication
drinking water. See water supply
driving injuries. See traffic injuries
drowning. See unintentional injuries
drug dependence, 907–931
abstinence-oriented treatments, 910–911
adolescents and, 1111
amphetamines, 922–923
interventions, 923
burden of disease associated with, 909, 914–916, 915t
cannabis, 917–919
interventions, 919
causes and health consequences of, 907–909
coke, 919–922
interventions, 921–922
cost-effectiveness of interventions, 912–913, 915t
comparing different interventions, 913–914
criminal justice interventions, 911–912
detoxification, 910, 912, 913
in developing countries, 916
drug-free treatment, 912–913
cost-effectiveness of, 913–914
ecstasy (MDMA), 923–924
heroin use
ancestors of, 907–908
health consequences of, 908–909
HIV infection and, 909
mortality and morbidity, 909
prevention of, 909–910
reducing heroin-related harm, 910
interventions, 909–916
methadone maintenance, 910, 911, 913
research and development agenda, 916
self-help groups, 911, 913
drug resistance, 1031–1051, 1332–1333
agenda for action and, 1045–1046, 1340
anthelmintic, 479
antibiotic use and. See antibiotics, indiscriminate use of
containing spread of resistant
micro-organisms, 1041–1042, 1340
diagnostic tests and, 1040
diarrheal diseases and, 378
disease burden and, 1033–1036, 1033t, 1034t, 1340
DOTS and. See directly observed therapy short course (DOTS)
drug quality and, 1040
drug treatment strategies and, 1037–1039
economic burden of, 1036–1037
global coordination and, 1042–1043
gonorrhea and, 1036
drug resistance (Continued)
helmint infections and, 479
history of, 122
HIV/AIDS, 358
humans and drug use, 314, 378,
1031–1032
integrated management of childhood
illness and, 1044
interventions, 1037–1044, 1038t
at patient level, 1040–1041
at provider level, 1039–1040
lessons learned, 1044–1045
malaria. See malaria
multi-drug resistant TB (MDR-TB), 289,
293, 294, 296, 297, 299, 301, 305, 1333
new drug development and, 1043–1044
pneumococci and, 1033–1034, 1045–1046
prescribing patterns and, 1039–1040
reducing selection pressure, 1039
research and development agenda, 1046
retail pharmacies and outlets and, 1040
risk factors and, 1031–1036
sexually transmitted infections, 314, 1036
shigella and, 1034–1036, 1045
surveillance and, 1042–1043
TB and, 294, 304–305, 1036,
1045–1046, 1333
transmission of resistant pathogens
and, 1033
drugs, 1323–1337
See also specific drugs and diseases
adherence of patient to therapy,
1330, 1346
for cardiovascular disease, 15–16,
650–654, 656, 658, 856–863, 859t,
862t, 863t
for cholesterol, 857
counterfeit, 1327
dispensing, 1330
doing drugs, 1329
distribution and storage, 1328–1329,
1345–1346
donated drugs, management of, 1329
financing of, 1330, 1332t
future challenges for, 1331–1334
generic, 1326, 1328
for hemoglobinopathies, 672
for influenza, 683b, 684
insulin. See insulin
for kidney and urinary system diseases,
699–700, 703
local production of, 1328
for malaria, 418–420
management of, 1345–1346
Model List of Essential Drugs, 1324–1325
for neurological disorders, 629, 631, 632,
634–635, 637, 640, 641
new product development, 141–144
drug resistance and, 1043
financing in developing countries, 150
R&D costs in developing countries,
142–143
R&D costs in industrial countries,
141–142
patent system and, 150–152
pharmacogenomics, 129, 129t
policies on, 1323–1324, 1345–1346
polypill. See polypill
prescription and use, 1039–1040,
1329–1330
pricing, 1326–1327
affordability, ways to increase, 150
differential or “tiered” pricing,
146–147
orphan drug acts, 147
procurement of, 1326–1327, 1345–1346
for psychiatric disorders, 605–606, 608,
609–610, 611, 612, 613, 618–619, 621
public education about, 98
quality assurance of, 1327
regulation of, 92b, 1345–1346
research and development agenda, 5b,
141–144, 1335, 1336t
for respiratory diseases of adults, 686–688
for rheumatoid arthritis, 974–975
sales tax exemptions on, 220
subsidies for medicines and medical
supplies, 217
for TB, 304
WHO prequalification process for,
1327–1328
Drugs for Neglected Diseases, 1323
drunk driving, 893, 894t
dysentery, 372, 378
See also diarrheal diseases
E. coli, 371–372
See also diarrheal diseases
Early Breast Cancer Trialists’ Collaborative
Group, 580
early childhood education, 221
earthquakes, 1149–1150, 1150t
East Africa
See also specific countries
development assistance for health to, 245
fluorosis of teeth in, 731
indoor air pollution and energy programs
in, 827–828
alcohol consumption interventions and,
899–900
contraception or family planning
and, 1086
CVD interventions and, 864
dengue and, 455
disasters, effect on, 1151–1152
helminth infection interventions and,
477–478, 478f
of high-technology medicine, 124–125,
133–134, 133t
improved health, effect of, 4b, 7–8, 165
of infectious disease outbreaks, 112b
leishmaniasis and, 455
maternal and perinatal conditions and,
522
quality of health care and, 1301–1302
school health interventions and,
1099–1101

1368 I Index
economic policies to encourage healthy behavior choices, 842–844
ecstasy. See drug dependence
eczema, 708
education
See also training of medical personnel adolescents and, 1115 on alcohol abuse, 893 on diabetes, 598 early childhood education, 221 of girls, 1095 on helminth infections, 472, 475 HIV/AIDS education campaigns, 344, 344b, 1105 on illegal drug use, 910 information, education, and communication campaigns, 176 life-skills and health education, 1115 on lifestyle changes for health, 837–838, 842, 859 on malaria, 422 malnutrition and school performance, 563 on osteoarthritis, 972 patient education, effect of, 98 peer education programs, 1115 referral hospitals’ role in, 1233–1234, 1234t on risk factors, 121 sex education, 344, 344b, 1121 Egypt diarrheal diseases in, 167, 176, 374, 378 food subsidy programs in, 216 health sector reform in, 1315 kidney and urinary system diseases and, 697 schistosomiasis in, 479 school health insurance program in, 187 El Salvador contracting for health care services in, 189 interpersonal violence in, 766 occupational health risks in, 1136b elder abuse, 756 See also interpersonal violence electrification, 795, 803–804, 810 electronic medical records (EMRs), 1300 ELISA. See enzyme-linked immunosorbent assay embryonic stem cells, 130 emergency medical services, 1261–1279 absence of ambulance system and, 1273b ambulances, 1267–1271, 1267t, 1270t burden of disease, 1262–1263, 1263t, 1274f communication systems for, 1267 costs and cost-effectiveness of interventions, 49, 1265–1266, 1266t, 1267t, 1268, 1270t deaths from trauma, 1278n1 defined, 1262 description of, 1261, 1262t disaster relief. See disaster relief documentation and quality assurance, 1272 equipment and supplies, 1266–1267, 1271–1272, 1275–1278t financing for, 1272 first aid, 1264 future challenges for, 1274 health facility-based system, 1271–1272 helicopter ambulances, 1268 interventions, 1263–1272 lay responders, 1264, 1267t, 1270t legislation on, 1272 lessons learned, 1272 malaria and, 1262 for newborns, 540–541 paramedical personnel, 1264–1265, 1270t cost-effectiveness of combining with lay responders, 1267t defined, 1262 planning and implementation of, 1272 prehospital care, 1264–1271 research and development agenda, 1272–1274 response time, 1265 training for hospital emergency workers, 1271, 1273b triage, defined, 1262 universal emergency care, 1271 emphysema. See chronic obstructive pulmonary disease (COPD) and asthma EMRs (electronic medical records), 1300 end-of-life care for HIV/AIDS patients, 351–353 end stage renal disease (ESRD). See kidney and urinary system diseases endangered species and traditional medicine, 1286 endemic treponematoses, 709 endoscopic surgery, 130 energy medicine, 1282 See also complementary and alternative medicine (CAM)
equity issues (Continued)
justice and special concern for the worst	off, 262–263
primary care and, 1198
referral hospitals and, 1239
sexually transmitted infections and, 318,
318t, 319t
eradication of infectious diseases,
1163–1176
See also infectious and communicable dis-
eases; specific diseases
ergonomics in workplace, 1137
Eritrea, malaria in, 418, 421
esophageal cancer, 570, 573
ESRD (end stage renal disease). See kidney
and urinary system diseases
Estonia
asthma in, 686
ethics, 259–270
See also equity issues
in choosing research priorities, 114,
265–269
in cost-effectiveness analysis. See
cost-effectiveness analysis
current controversies in research ethics,
267–269
discrimination against persons with
disabilities, 264–265
fair chances and best outcomes in terms
of, 264
genomics era and, 135
goals of ethical review of research,
266–267
in health resource allocation, 259–265
hemoglobinopathies and, 670, 678
informed consent of human research sub-
jects, 266–267, 269
placebo controls and, 268
responsibility for health needs, 265
rights of host communities and, 268–269
standard of care and, 267–268
state secrets of experimentation with
human subjects, 269n1
in stem cell therapy, 130
Ethiopia
African trypanosomiasis in, 458
child mortality in, 544b
dental treatment in, 729
development assistance for health
to, 245
diarrheal diseases in, 378
health care expenditures in, 245
leprosy in, 444
malaria in, 414, 421, 426
maternal deaths in, 544b
neonatal deaths in, 531
skin diseases in, 708, 709
Europe
See also specific countries
cardiovascular disease in, 649, 654, 655t,
656t
cleft lip and palate in, 731
diarrheal diseases in, 378
food manufacture in, 845
hemoglobinopathies in, 670, 673
heroin use in, 908
HIV/AIDS, proposed guidelines for,
348–349
kidney and urinary system diseases in,
695, 698, 700
mental disorders in, 618, 619
occupational lung diseases in, 690
road traffic injuries in, 746
salt fluoridation in, 726
sexual risk behaviors in, 312
strokes in, 634
transportation choices in, 840
vaccine-preventable diseases in, 394, 399,
400, 402, 408
European Program for Intervention
Epidemiology Training, 1002
European Union approval of
pharmaceutical products, 152–153
evidence-based medicine, 121, 144,
1001, 1026t
excreta disposal. See sanitation
improvements
exercise. See physical activity interventions
Expanded Program on Immunization
(EPI), 44, 121, 383, 389, 397, 405b,
1177, 1186, 1324, 1347
eye disease
See also blindness; onchocerciasis;
trachoma
diabetes and, 597
fall-related injuries. See unintentional
injuries
family care leave, 221
family planning, 1075–1090
See also contraception
cost-effectiveness as intervention, 203
fertility behavior change, 510
organization of programs, 1081
social marketing of, 1081
successful programs in, 167
time interval between
pregnancies, 1079
vertical vs. integrated programs,
1081, 1085
family violence, 756
See also interpersonal violence
FDA. See U.S. Food and Drug
Administration
fetal alcohol syndrome, 936b
fetal monitoring during childbirth, 948
fibromyalgia, 965
financing, 16–21, 225–242
See also fiscal policies to promote health
absorptive capacity of countries,
232–233, 232t
aid effectiveness, 23, 192–193, 233,
250–256
MDGs and, 185, 192–193
reaching local communities, 255–256
challenges and transitional nature of,
239–240
composition of health financing by region
and income level (2001), 230t
for contraception, 1332t
by country income level (2001), 18, 18t
development assistance. See development
assistance and health policy
distributing and sourcing health
expenditures, 229
district hospitals and, 1210–1221
for drugs, 1330, 1330t, 1332t
for emergency medical services, 1272
fiscal sustainability, 233
functions involved in, 225–227, 226f
for health information systems,
1018–1019
for health promotion and disease
prevention, 211–223
in low-income countries, 5b, 20–21,
211–212, 234–236
community-based health insurance,
231, 236
needs gap, 234
new global alliances and funds, 234
PRSPs, 235–236
macroeconomic consequences of aid,
23–24
MDGs requirements, 185–193, 191b, 192t
in middle-income countries, 5b, 19–20,
236–239
alternative risk pooling arrangements,
236–238
donor disengagement from,
238–239
national health services, 238
private health insurance, 238
single pool vs. virtual single pool, 238
sources of financing, 238
universal coverage initiatives, 236, 237–238, 237t
mobilizing government revenues, 229–231
models of, 226
national health service (NHS) model, 226, 238
for new product development, 146–150
pharmaceutical firms in developing countries, 150
private sector, 146–147
public-private partnerships, 147–150, 149t
public sector, 146
Poverty Reduction Strategy Papers (PRSPs) and, 235–236
for primary care, 1199–1200, 1200t
private foundations, role of, 182, 225–225
See also specific foundations
private insurance model, 226, 238
project support vs. budget support, 238
purchasing, 226
reallocation based on cost-effective criteria, 5b, 186
revenue sources, 226, 227, 231t, 240n2
risk pooling, 226, 227–232, 236–238
social insurance model, 226
SWaps, 234–235
trends by country income level, 231–232, 231f
for vaccines, 406–407, 1331, 1332t
Finland
CVD and lifestyle changes in, 837, 837b
diabetes and lifestyle changes in, 593
rheumatoid arthritis in, 974
tobacco taxes in, 882
firearms and violence, 760, 763, 765
See also interpersonal violence
first aid, 1264
fiscal policies to promote health, 211–223
family care leave, 221
lessons in using, 222t
in low-income countries, 211–212
maternity leave, 221
sick leave, 221
subsidies for health and health-related products, 212–218, 212t, 213–214t
consumer subsidies, 212–218
producer subsidies, 218
taxes. See taxation
workplace health, 220–221
fiscal sustainability, 233
fluoridation, 792
dental caries. See dental caries
negative health effects of, 821
FOCUS on Young Adults, 1114, 1115t
Focusing Resources on Effective School Health (FRESH), 784, 1096, 1096t, 1097, 1098b, 1099, 1101, 1102–1103t
folic acid, 836, 842, 939, 940–941, 948
folklore and alternative medicine, 1282
food. See nutrition
food manufacture, 841–842, 856
foot problems and diabetes, 597
foreign direct investment and health gains, 8
Framework Convention on Tobacco Control, 882
Framingham, Massachusetts, study of males and heart disease, 120, 855
France
homeopathic products, use in, 1282
skin diseases in, 714
free trade agreements, 1141
FRESH. See Focusing Resources on Effective School Health
fuel choice and air quality. See indoor air pollution
full income, 8–9, 9f
defined, 4b, 8
fungal infections of skin, 713–715
Gambia
malaria in, 418
respiratory diseases of children in, 492
GATB. See Global Alliance for TB Drug Development
GAVI. See Global Alliance for Vaccines and Immunization
gender differences, 195–210
See also women
African trypanosomiasis and, 456
background, 195–197
burden of disease and, 197–198
disasters and, 1149
hearing loss and, 958
leishmaniasis and, 455
mental disorders and, 605
research agenda, 206–207
sex distinguished from gender, 196
sexually transmitted infections and, 318
vision impairment and, 955
general primary care. See primary care
generic drugs, 1326, 1328
genetic disorders
hemoglobinopathies and, 669–670, 671, 672, 678
See also hemoglobinopathies
kidney disease and, 696
mental disorders and, 605
genetically modified crops, 131–132
genetics
diabetes and, 593
helminth infections and, 470
hemoglobinopathies and, 673
insulin resistance syndrome and, 834b
genital herpes, 312
See also sexually transmitted infections (STIs)
genital mutilation, 761, 763
genomics, 107–109, 126–130, 128b, 133, 135
Genomics and World Health (WHO report), 127, 133, 135
Germany
homeopathic products, use in, 1282
influenza in, 684
transportation choices in, 840
universal coverage approach of, 237
GFHR. See Global Forum for Health Research
Ghana
breastfeeding programs in, 559, 561
deworming programs in, 478
emergency transport to hospital in, 1264
food fortification in, 558
health sector support program in, 251
malaria in, 1092
medical workers in, 1309
newborn survival rates in, 540
organizational structure of health systems in, 93, 1345
road traffic injuries in, 746–747
sexually transmitted infections in, 323, 325
traditional medicine in, 1283–1284
gingivitis, 729–730
See also oral and craniofacial diseases and disorders
Global Alliance for Improved Nutrition, 182, 254
Global Alliance for TB Drug Development (GATB), 140, 142
Global Alliance for Tuberculosis, 182
Global Alliance for Vaccines and Immunization (GAVI), 24, 182, 234, 244, 245, 253, 389, 397, 406, 491, 492, 493
Global Burden of Diseases 2000 study (World Health Organization), 613
Global Campaign against Epilepsy, 631
Global Forum for Health Research (GFHR), 106, 114, 157, 161, 749
Global Fund to Fight AIDS, Tuberculosis and Malaria, 110, 147, 182, 234, 243, 245, 305, 332, 425, 1333
Global HIV Prevention Working Group, 332
Global Immunization and Vision Strategy, 394
Global Initiative on Children’s Environmental Health Indicators, 812
Global Polio Eradication Initiative, 1347
Global Programme against AIDS, 14
Global Programme for the Elimination of Lymphatic Filariasis, 439, 440
Global Strategy on Diet, Physical Activity, and Health, 219
global surveillance networks, 1011–1012, 1012f
global warming, 104b, 118
globalization, effect of, 3, 104, 104b, 1140–1141
glomerulonephritis, 696–697
See also kidney and urinary system diseases
goiter, 554
gonorrhea. See sexually transmitted infections (STIs)
gout. See musculoskeletal disorders
government reform and health care delivery, 90–91
to meet MDGs, 185–190
Grand Challenges in Global Health, 115
Greece
dengue in, 452
hemoglobinopathies in, 669, 673
malaria in, 421

growth faltering. See stunting, wasting, and micronutrient deficiency disorders
Guatemala
field epidemiology in, 1002
food fortification in, 558, 562
indoor air quality and energy programs in, 190, 811
interpersonal violence in, 766
occupational health risks in, 1136b
performance-based contracts with NGOs in, 252, 252b
guinea worm eradication, 167, 169, 176, 779, 1173
Gulf Cooperation Council Group Purchasing Program, 1327
guns and violence, 760, 763, 765
See also interpersonal violence
H. pylori infection, 569, 573, 574
Haddon matrix, 739

Haemophilus influenzae type B (Hib).
  See Hib disease prevention
Haiti
contracting for health care services in, 188, 1299
HIV/AIDS in, 358
malaria in, 413
performance-based contracts with NGOs in, 252
hand washing as intervention, 187, 189–190, 377, 379, 556, 1041
Harvard lifesaving study, 39b
HBV vaccine, 572–573
healers, use of in traditional medicine, 630, 1283, 1286–1287
health care organizations, specificities of, 1341b
health care workers. See medical workers
health education. See education
health gains, 5–6
See also specific diseases, regions, and countries
effect on economic welfare, 4b, 7–9
lessons of experience, 165–179
linked to research, 160–161
research methods on, 166
successful programs for behavioral change interventions, 175–177, 175b
cases selected for study, 166–169
combination or bundled interventions, 178
demand-side incentives, 175
environmental control interventions, 177–179
intervention type, programmatic characteristics, and policies, 170–178
product-intensive interventions, 171–173, 171b
service-intensive interventions, 173–175, 173b
health information systems.
  See information systems
health insurance
community-based, 231, 236
private, 231, 238
universal coverage approaches, 236, 237–238, 237t
health management information system (HMIS), 1017
Health Metrics Network (HMN), 1020b
health policy
See also policy instruments
challenges for, 6–7, 1339–1340
cost-effectiveness and, 36b
IMCI and, 1177–1178

health systems
adolescents and, 1122
assessment of approaches to, 91–97
capacity of defined, 86n3
low-capacity environments, solutions in, 98–99, 99t
civil service reform and, 96
constraints on delivery, 89–91, 89t, 90t, 1340
cost-effective interventions aimed at, 27, 53–58

CRIS in, 107
health care organizations, specificities of, 1341b
history and current themes, 88–89, 107
horizontal approach to. See horizontal approach to health systems
human resources. See medical workers
IMCI and, 1178
improving quality, effect of, 188–189, 1178
inequities in. See equity issues
information and surveillance. See information systems; surveillance
lack of information on, 99–100, 100b
management. See management of health services
mass campaigns, 88
occupational health and, 1141–1142
organizational structures and financing of, 92–94
outsourcing management of, 93–94, 93b
primary care and, 1195–1196
quality assessment and assurance, 96–97
regulatory approach, 91–92, 92b, 96, 97
research and development agenda, 99–100, 116
service-level mechanisms, 98, 1340
stewardship approach, 91–92
strategic purchasing by, 1348–1349, 1349f
strengthening of, 87–102, 1002
successes of, 88
surveillance. See surveillance
sustainability of, 233

systems-level mechanisms, 97–98
vertical approach to. See vertical approach to health systems
weak, 99, 1340
health workers. See medical workers
hearing loss
acute ear infections in children, 484
aging and, 958
causes and epidemiology of, 953, 957–960, 958t
chronic middle ear infection, 959
cost-effectiveness of interventions, 954t
gender differences and, 958
hearing aids, 960
interventions, 959–960
mortality and, 958–959
research and development agenda, 960
risk factors for, 958
years lived with disability and
DALYs, 959
*helicobacter pylori*. See *h. pylori infection
helicopter ambulances, 1268
helminth infections, 467–482
See also guinea worm eradication
adolescents and, 1116
age-associated prevalence of, 469, 469f
burden of, 470–471, 476–477
demographics and characteristics of, 467–468
control of, 478–479, 783–784
costs and cost-effectiveness of interventions, 46, 472–476, 475t
deworming (anthelmintic drug treatment), 472–474
school-based, 473, 474–475, 1092, 1098b
economic benefits of interventions, 477–478, 478f
education and communication about, 472, 475
epidemiology of, 468–470
excreta disposal and, 783–784
global prevalence and distribution of, 467, 468t
preschool children and, 473, 474
research and development initiatives, 479–480
risk factors for, 470
sanitation improvements and, 472
school-age children as high-risk population for, 473, 474, 476, 1092, 1098b
selective treatment, 472
soil-transmitted, 467–468
targeted treatment, 472, 476
universal treatment, 472, 476b
water supply and, 779
hemoglobinopathies, 663–680, 669–672
bone marrow transplantation, 669, 672, 675, 677, 678
burden of, 667–669, 669t
clinical features, 664
costs and cost-effectiveness of diagnosis and management, 673–677, 674t, 675t
thalassemias, 673–675, 674t, 675t
ethical and social issues, 678
future research needs, 678–679
global distribution and frequency of, 665–667, 665f, 666f, 666, 667f
HIV/AIDS and, 670
international and national support groups, 678
interventions, 45, 670–671, 677–678
normal hemoglobin, 663
population genetics and dynamics, 664–665
prevention, 669–670
research priority of, 126
screening and carrier detection, 671
sickle cell diseases. See sickle cell anemia and related diseases
spectrum of inherited hemoglobin disorders, 663–664
thalassemias. See thalassemias
*hepatitis B*
burden of, 396
cancer and, 569
injecting drug users and, 315, 909
occupational risk of health care workers for, 1130, 1130f
sexual transmission of, 315
vaccine for, 121–122, 244, 315, 389, 396, 406, 1324, 1325
See also vaccine-preventable diseases
*hepatitis C*
hemoglobinopathies and, 670
injecting drug users and, 909
occupational risk of health care workers for, 1130, 1130f
sexual transmission of, 315
vaccine for, 121–122, 244, 315, 389, 396, 406, 1324, 1325
See also vaccine-preventable diseases
*herpes simplex virus*. See sexually transmitted infections (STIs)
*H5N1 influenza*. See avian influenza threat
*Hib disease prevention*, 167, 172, 244, 389, 396, 1324
See also vaccine-preventable diseases
burden of disease, 396
for children, 485–486, 491–492
*high blood pressure*. See cardiovascular disease (CVD), subheading: hypertension
*high-income countries*
See also specific countries
breast cancer screening in, 578
cancer diagnosis and treatment in, 559, 582–583
combination of high blood pressure, cholesterol, and obesity in, 859–860, 863
morpheine use for pain in, 984–985
neonatal deaths in, 531
smoking restrictions in, 876
hip replacement surgery, 973
historical achievements in medicine, 119–120
HIV/AIDS, 13–14, 331–369
See also specific countries and regions
action under uncertainty, 333–347
adolescents and, 1112
anemia in AIDS patients, 359–360
antiretroviral treatment for.
See antiretroviral drugs (ART)
blood safety practices as prevention of, 346
blood screening for, 346, 348
blood transfusion and, 346–347
bloodborne transmission, 346–347
breastfeeding and, 334, 336, 375
burden of, 333, 334t
chemoprophylaxis to treat, 349, 354
circumcision as possible protection against, 320, 322, 360b
community health and nutrition programs and, 1070–1071
centennted epidemic, 348–349
condom use for prevention, 167, 170, 176–177, 216, 345, 348b, 1080
low levels of use, 184
costs and cost-effectiveness of interventions, 356t
based on mode of transmission, 344–345
prevention interventions, 336–347
school-based prevention programs, 1105
successful prevention programs, 336–347, 339–343t
development assistance in response to, 244, 245
diagnostics development for, 144, 351
discrimination against HIV-positive individuals, 109
drug resistance and, 358
drug therapy for, 1333
economic effects of, 8, 9
epidemic profiles to develop prevention guidelines, 347–349
fungal infections and, 714
general interventions for transmission of, 344–345
generalized high-level epidemic, 349
generalized low-level epidemic, 349
health challenge of, 4b, 7, 88
hemoglobinopathies and, 670
infected blood or blood products, exposure to, 335
infection, determinants of, 333–336
infectivity, 334–335
HIV/AIDS (Continued)
injecting drug users and, 335, 346, 909, 913, 917, 920
interventions, 4b, 43, 344–345, 350–360, 360b
kidney disease and, 697
laboratory monitoring of immune function as guide for therapy, 358–360
leishmaniasis and, 453
life expectancy, effect on, 6, 106
low level epidemic, 347–348
malaria and, 418
monitoring of immune function to guide therapy, 358–360
monitoring toxicity, 359–360
mother-to-child transmission (MTCT), 332, 336, 339–343t, 345–346, 345b, 376
neurological problems in children with, 935b
nutrition programs and food security, 352–353
obstacles to control, 331–333
occupational risk of health care workers for, 1130, 1130f
opportunistic infections (OIs) and, 353–355, 353f, 1339
oral manifestations of, 730
pain control for. See palliation
peer-based intervention programs for, 344–345
perinatal transmission, 335–336
prescribed therapy, adherence to, 358
prevention and management, 13–14, 43, 167, 348b
psychological support, 352
rape and, 758
referral hospitals and, 1239
research and development agenda, 114, 360–361, 360b
respiratory disease associated with, 485, 489
response to therapy, 359
rigorous evaluations, lack of, 332–333
school-age children and, 1092–1093, 1093f
cost-effectiveness of school-based prevention programs, 1105
second-line and subsequent therapies, 358
sex education and, 344, 344b
sexual transmission of, 334–335, 334t interventions to prevent, 345
sexually transmitted infections and, 314, 345
skin diseases of, 707, 708, 709, 717
successful prevention programs, 332b, 336–347, 348b
symptom-based care, 352
TB and, 291, 292–293, 294, 301, 302, 304–305
universal precautions, 346
vertical transmission, 335–336
voluntary counseling and testing (VCT), 332, 336, 344, 347, 348, 349
women and, 195, 196
workplace health and, 221
HMN (Health Metrics Network), 1020b
home-based care, 1204, 1343–1344
homeopathy, 1282–1283, 1283t, 1285, 1020b
HMN (Health Metrics Network), 1020b
home-based care, 1204, 1343–1344
homeopathy, 1282–1283, 1283t, 1285, 1020b
human T cell lymphotropic virus, 315
hurricanes, 1151
hygiene. See hand washing as intervention; sanitation improvements
hyperpigmentation, 718
hypertension, 15
See also cardiovascular disease (CVD)
hyperthyroidism, congenital,
945–946, 949
hypothyroidism, 627
hypoxemia diagnosis, 488
IAEA. See International Atomic Energy Agency
IAVI. See International AIDS Vaccine Initiative
The ICD–10 Classification of Mental and Behavioral Disorders (ICD-10)
(WHO 1992), 606t
ICPD. See International Conference on Population and Development
IDSR (Integrated Disease Surveillance and Response), 1003–1004
IIF. See International Finance Facility (IFF) proposal
IHD. See ischemic heart disease
illicit opiate abuse. See drug dependence
ILO. See International Labour Organization (ILO) on occupational health risks
ILO–WHO Joint Committee on Occupational Health, 1131
IMCI. See integrated management of childhood illness
immunizations. See vaccine-preventable diseases; vaccines: specific diseases
imprisonment for dependent illicit opioid use, 911–912
improved health
See also health gains
lessons of experience, 165–179
value of, 158–160
incentive pay to medical providers, 4b, 94–95, 95b, 170, 1299, 1310–1311, 1313–1320
community workers, 1063
income levels and health gains, 6
INDEPTH (International Network of Field Sites with Continuous Demographic Evaluation of Populations and Their Health in Developing Countries), 1021
India
ambulances in, 1268
arsenic contamination of water in, 821
asthma in, 688
Bhopal catastrophe, 819, 819b, 1133, 1149
breast cancer in, 578, 584
burn-related injuries in, 741
cardiocvascular disease in, 658, 659, 861, 863t
cataract surgery in, 1258b
child survival in, 1068
combination of high blood pressure, cholesterol, and obesity in, 853–854, 861, 863t
community-based programs in,
1064, 1066
dengue in, 452
dental treatment in, 729
development assistance for health to, 245
diabetes in, 597, 1333
diarrheal diseases in, 372, 377, 378
district hospitals in, 1217
drug addiction in, 908
emergency medical care in, 1273b
epilepsy in, 630
food fortification in, 558
food subsidies in, 216
hemoglobinopathies in, 664, 665, 668, 670
HIV/AIDS in, 254, 358
immunization services in, 404b
indoor air quality and energy programs in, 190, 809, 809b
Integrated Child Development Services Program, 556
Kaposi’s sarcoma in, 730
kidney and urinary system diseases in, 695, 697, 700, 702, 703
leishmaniasis in, 452, 459, 461
leprosy in, 437, 445
lymphatic filariasis in, 436, 439, 440, 442, 443
malaria in, 414, 418
morphine use in, 990–991
National Cancer Registry program, 1009
neonatal deaths in, 531, 545, 545b
neurological disorders in, 628
occupational risks of silica dust in,
1137, 1138b
performance-based contracts with NGOs in, 253
quality of care in, 1298
rotavirus vaccine in, 377
skin diseases in, 714, 715
smallpox eradication in, 1163, 1170
strokes in, 633
TB in, 253, 291
training for emergency medical personnel, 1273b
vaccine-preventable diseases in, 404b, 406
vital events registration in, 1021
water pollution in, 821, 825b, 828
water supply in, 773–774
women in, 195
Indonesia
avian influenza in, 682b
community-based programs in, 1064
dengue in, 459
dental caries in, 725
diarrheal disease in, 1303
kidney and urinary system diseases and, 697
leprosy in, 441
maternal deaths in, 533
mental disorders in, 621
neonatal deaths in, 533
polio in, 1170
rice subsidy in, 216
skin diseases in, 708, 715
smallpox in, 1163
TB in, 291, 295, 296
tsunami in, 1149
indoor air pollution, 190, 793–815
causes and burden of, 793–799
COPD and, 688, 690, 691–692, 804, 805
costs and cost-effectiveness of interventions, 799–808, 801b, 802b
cost assumptions, 804
cost-benefit analysis, 807–808, 808t
cost-effectiveness analysis, 804–807, 806t, 812
effectiveness assumptions, 804–805
implementation period, 805
DALYs and deaths due to, 797, 798t
economic effects of fuel collection, 797
electrification in rural areas, 795, 803–804, 810
environmental consequences of, 797–798
fuel subsidy programs to control, 217
health impacts of, 795–796, 796t, 797t
interventions and policy, 799, 800–801t
kerosene and LPG as cleaner fuels, 803, 805, 810, 811b
lack of lighting and, 797
lessons learned, 808–811
levels of pollution and exposure, 793
MDGs on poverty reduction and, 799, 812
method used for determining attributable disease burden, 796
research and development agenda, 811–812
solid fuel use, 797
infant care. See perinatal conditions
infant mortality. See child mortality rates
infectious and communicable diseases
See also specific diseases
burden of, 105
colonization efforts and control of, 120
cost-effective interventions for, 53
disasters and, 1151, 1154
distinguished from eradication, 1165
economic considerations, 1167–1169
elimination of, defined, 1165
eradication of, 1163–1176
See also specific diseases
certification process for, 1167
defined, 1164
distinguished from control, 1165
distinguished from eradication, 1165
disasters and, 1151, 1154
defined, 1165
economic considerations, 1167–1169
geographic and environmental factors, 1165–1166
interventions to block transmission, 1166–1167
laboratory containment and, 1166
local vs. international net benefits, 1167–1168
natural resistance to reinfection and, 1166
operational considerations, 1166–1167
potential reservoirs and, 1166
private vs. social net benefits, 1167
scientific considerations, 1165–1166
short-term vs. long-term net benefits, 1167
surveillance and, 1166
transmissibility and, 1166
vertical vs. horizontal programs, 1168–1169
extinction of, defined, 1165
gene therapy and, 127
kidney disease and, 697
Index
informational and communicable diseases (Continued)
new diseases since 1970, 112b, 122
partial control of, 121–122, 125
research and development agenda, 106, 132
skin diseases. See skin diseases
water-related diseases, 775–776, 775t, 776t
infective endocarditis, 647
See also rheumatic heart disease
INFECTOM (Information, Feedback, Contracting with Providers to Adhere to Practice Guidelines, and Ongoing Monitoring), 1303
See also respiratory diseases of adults and, 597
influenza pandemic, possibility of, 4b, 7, 106–107
See also avian influenza threat
information, education, and communication campaigns, 176, 178, 187, 475
condom use, 1084
rheumatoid arthritis, 967
information, value of (VOI), 161–163, 162b
information systems, 1017–1030
benefits of improved information, 1023–1024
collection, management, and analysis systems, 1019–1022
costs and cost-effectiveness of improved information, 1023–1027, 1024t, 1025t, 1027t
data collection, 1019–1022
direct expenditures for health information, 1018–1019
dissemination and use of health information, 1023, 1297, 1305–1306
district hospitals and, 1216
electronic medical records (EMRs), 1300
financing of, 1027–1028
health service statistics, 1021–1022
information and communication technologies (ICT), 1022
Internet access, 1022
lessons learned, 1028
national census, 1020
national health account (NHA) framework, 1022
policy on information, 1019
research and development agenda, 1028–1029
resource-tracking subsystem, 1022
sample surveys, 1020
sources outside of health sector, 1019t
strengthening of systems, 1023
surveillance. See surveillance
user fees to help support, 1019
verbal autopsies, 1021
vital events monitoring, 1021
information technology, potential of, 117
informed consent of human research subjects, 266–267, 269
inherited disorders of hemoglobin. See hemoglobinopathies
Initiative for Vaccine Research Department (WHO), 407
Initiative on Public-Private Partnerships for Health, 148
injuries, 16
See also interpersonal violence;
unintentional injuries
adolescents and, 1111
alcohol use and, 890
burden of, 107
costs and cost-effectiveness of interventions, 48–49
emergency care and, 1263
occupational injuries. See occupational health
prevention strategies, 48–49
surveillance, 1007–1008
Injury Surveillance Guidelines (WHO), 1007
insecticide-treated nets (ITNs) for malaria prevention, 217, 421, 423, 424t, 425, 556, 1041
Institute of Medicine (IOM; U.S.)
on global action on drug resistance, 1043
on quality of medical care, 17, 17b, 599, 1293, 1294–1295, 1295b
insulin, 593, 596, 1328
insulin resistance syndrome, 834b
Integrated Disease Surveillance and Response (IDSR), 1003–1004
integrated management and treatment of TB, 295
integrated management of childhood illness (IMCI), 1177–1191
antimicrobial drug provision and, 1185b
causes and burden of child mortality, 1177
challenges when weak health systems, 99
CHNs and, 1056
costs and cost-effectiveness of interventions, 50, 1180–1184, 1181f
on diarrheal diseases, 376, 384
district hospitals and, 1215
drug resistance and, 1044
equity issues and, 1184
family and community practices and, 1178, 1180, 1185–1186
future potential of, 1189–1190
health systems and, 1178, 1187–1188
health workers and, 1178, 1186
interventions, 1178–1180
lessons learned, 1184–1188
management process, 1179f
Multi-Country Evaluation of IMCI
Effectiveness, Cost, and Impact (MCE), 1181–1184, 1183b
newborn care and, 545b
policy shift to, 1177–1178, 1187
research and development agenda, 1188–1189
integration of medical sciences in future, 132–133
intellectual property and drugs, 150–152
intentional injuries
costs and cost-effectiveness of interventions, 48
Inter-Agency Coordinating Committee, 172
Inter-American Development Bank, 1149
International AIDS Vaccine Initiative (IAVI), 182, 244, 254, 255b
International Atomic Energy Agency (IAEA)
African trypanosomiasis and, 460
International Centre for Diarrheal Disease Research, 374
International Classification of Functioning, Disability, and Health (WHO), 937, 953, 957
International Code of Marketing of Breastmilk Substitutes, 539
International Conference on Population and Development (ICPD), 499, 513, 1095
International Council for the Control of Iodine Deficiency Disorders, 559
International Diabetes Federation, 597
International Dispensary Association, 1326
International Energy Agency, 794, 810
International Finance Facility (IFF) proposal, 234, 250
International Foundation of Dermatology, 708
International Labour Organization (ILO) on occupational health risks, 1128, 1129, 1130, 1135, 1140
ILO–WHO Joint Committee on Occupational Health, 1131
WHO–ILO Joint Effort on Occupational Health and Safety in Africa, 1134
WISE (Work Improvement in Small Enterprises), 1133
International League against Epilepsy, 631
International Monetary Fund (IMF) on AIDS impact on full income, 9 criticisms of structural adjustment programs and fiscal ceilings of, 233 Poverty Reduction Strategy Papers (PRSPs), 235–236
International Network of Field Sites with Continuous Demographic Evaluation of Populations and Their Health in Developing Countries (INDEPTH), 1021
International Partnership for Zinc Nutrition Consultative Group, 554, 565
Internet access, 1022
kangaroo mother care, 540
Kaposi’s sarcoma, 730
Katayama Syndrome, 468
Kazakhstan
  cardiovascular disease in, 649, 649t
Kenya
  African trypanosomiasis in, 458
  drug dispensing in, 92b
  fluorosis of teeth in, 731
  helminth infections in, 475
  HIV/AIDS in, 336
  hospitals in, 1217, 1218, 1219t, 1343, 1345, 1348
  IMCI program in, 1180
  indoor air pollution in, 795, 802–803, 802b
  interpersonal violence in, 757
  malaria in, 418, 426, 1092
  onchocerciasis in, 440
  pain control for cancer in, 986b
  road traffic injuries in, 749b
  traditional medicine in, 1283, 1285, 1286
  water supply in, 773
Kenya Medical Research
  Institute–Wellcome Trust Collaborative Research Programme, 92b
kidney and urinary system diseases,
  695–706
  acute renal failure, 698
  benign prostatic hypertrophy, 698
  burden of, 695–696, 696t
  causes of diseases of, 696–698
  diabetes and, 698
  economic benefits of interventions, 700–702, 701t
  future challenges for, 704
  genetic diseases, 696
  glomerulonephritis, 696–697
  HIV/AIDS and, 697
  hypertension and, 698
  implementation of control strategies, 702–703
  infections, stones, and obstructive uropathy, 697–698
  interventions to delay CKD (chronic kidney disease), 699–700
  prevention of kidney failure, 703
  renal replacement therapy (RRT), 698, 703
  research and development agenda, 703–704
  risk factors for kidney disease, 699
  scabies and, 710
  schistosomiasis. See schistosomiasis
  TB and, 697
  teaching and research centers, establishment of, 703
knee replacement surgery, 973
knowledge
  See also information systems
  diffusion of, 5b, 103, 117, 187
types of, 110
Koch, Robert, 119
Korea, Republic of
  drug prescribing and dispensing in, 1346
  Industrial Safety and Health Act, 1140
  neonatal deaths in, 1152, 1152t
Kuznets curve, 749b
*Lancet* on need for new health systems research specialty, 99
Lao People’s Democratic Republic
  drug policy in, 1346
  water pollution in, 829
Latin America and Caribbean
  See also specific countries
  abortions in, 1078
  burn-related injuries in, 741
  cardiovascular disease in, 650, 654, 655t, 656, 656t
  Chagas disease in, 167, 436, 442, 446
  contraceptive use in, 1076, 1080, 1086
  dengue in, 452, 454–455, 459, 461
  development assistance for health to, 245
  diabetes in, 597
  diarrheal diseases in, 373
  disasters, impact in, 1152, 1152t
  ecstasy (MDMA) use in, 924
  excreta disposal in, 780
  food subsidy programs in, 216
  hurricanes in, 1151
  indoor air pollution in, 803
  interpersonal violence in, 757
  leishmaniasis in, 453
  lymphatic filariasis in, 440
  malaria in, 414, 421
  mental disorders in, 619, 622
  newborn mortality in, 533
  occupational health risks in, 1128, 1135, 1136b
  onchocerciasis in, 441, 957
  performance-based contracts with NGOs in, 252
  proposed guidelines for HIV/AIDS in, 348–349
  referral hospitals in, 1239
  road injuries in, 1111
  salt fluoridation in, 726
  sector adjustment loans to, 251
  vaccine-preventable diseases in, 400, 402, 408
  water supply in, 771, 772, 773, 774, 776
  yellow fever in, 396–397
LDDs. See learning and developmental disabilities
lead exposure, 820
learning and developmental disabilities (LDDs), 933–951
  attention deficit hyperactivity disorder (ADHD), 935b
  autism, 935b
  burden of, 934–937
  causes of, 934t
  community-based rehabilitation and, 946–947
  congenital hyperthyroidism, 945–946
  costs and cost-effectiveness of interventions, 933
  community-based rehabilitation, 937
  food fortification, 940–941
  neonatal screening, 943, 945–946
  Down syndrome, 941–945, 944t
  education and work and, 933
  environmental exposures, 936b
  fetal alcohol syndrome, 936b
  impairment, disability, and participation levels of, 937
  interventions, 933, 935–936b
  in low- and middle-income countries, 938–948, 939t
  lifelong duration, 933
  neurological disabilities of childhood, 935b
  prevalence, 933, 937–938
  prevention levels, 937
  research and development agenda, 948
  unintended consequences of successful or partially successful interventions, 937
Lebanon
  air pollution in, 828
  hemoglobinopathies in, 670
legislation
  cigarette and tobacco use warnings, 168, 876
  drunk driving, 893
  first public health act in UK, 120
  food advertising and, 842
  food manufacture and, 841
  illicit opioid use, 911–912
  occupational health, 1131–1132
  road safety, 747, 893
  smoking bans in public places, 875–876
leishmaniasis
  burden of, 455–456
  characteristics and transmission, 452–453
  costs and cost-effectiveness of interventions, 46, 459
economic impact of, 455
HIV/AIDS and, 453
management and control strategies of, 457–458, 461–462
social impact of, 455–456
vaccine development for, 462
leprosy
burden of, 437
characteristics and transmission, 435–436
costs and cost-effectiveness of interventions, 444–445
interventions and effectiveness of, 441
patterns of skin diseases in community and, 709
skin depigmentation in, 715
leukemia, 315
levels of care
community level. See community-based programs and treatment
district hospitals. See district hospitals
general primary care. See primary care referral hospitals. See referral hospitals
LF. See lymphatic filariasis
life expectancy, increases in, 3, 4b, 6, 6t, 103
See also mortality rates
valuing of, 157–163
of women, 5, 5f, 197, 201–202
lifelong medical management, 4b, 27, 116
lifestyle
See also specific lifestyle choice
(e.g., alcohol use, tobacco use)
cancer and, 569, 833
cardiovascular disease and, 647, 649, 652, 659, 833–836
chronic diseases and, 833–836, 834t
combination of high blood pressure, cholesterol, and obesity and, 860–863
diabetes and, 593, 1333
helminth infections and, 470
neurological diseases and, 634
taxation to discourage high-risk behaviors, 177
liquid petroleum gas, 217, 803, 805, 810, 811b
Live for Life (Johnson & Johnson), 838b
liver cancer, 569, 570, 572, 573, 574
local level. See community-based programs and treatment
Louisiana and free condom distribution program, 216
low birthweight
cardiovascular disease and, 121
as cause of neonatal death, 534, 540
diabetes and, 121
malaria and, 418
low-income countries
See also specific countries
burden of disease in, 31t
cancer diagnosis and treatment in, 582–583
causes of deaths in, 30t
combination of high blood pressure, cholesterol, and obesity in, 860–863
diagnostics development in, 144
drug abuse, illicit, 916
financing health in, 5b, 20–21, 27, 229–231, 234–236
See also financing
fiscal policy for health in, 211–212
morphine use for pain in, 985
neonatal deaths in, 531, 547b
new product development in, 142–143
private spending on health in, 231
LPG Rural Energy Challenge, 810
lung cancer
clinical epidemiology and, 120
indoor air quality and, 795
mortality rates and, 570
occupational risk of, 1128, 1128t, 1129, 1130
screening for, 574–575
pharmaceutical use and, 573, 871–872, 872f
workers’ risk for asbestos and smoking exposure, 1128, 1128t
lymphadenitis, 435
lymphatic filariasis (LF)
burden of, 436
characteristics and transmission, 434
costs and cost-effectiveness of interventions, 445–446, 442–443, 443t
interventions and effectiveness of, 439–440
skin diseases and, 709
macroeconomic consequences of aid, 23–24
Madagascar
breastfeeding programs in, 559, 561
cervical cancer screening in, 576, 577t
contracting for health care services in, 188
influenza in, 684
leprosy in, 437
malaria in, 414
oral health and education program in, 726
sexually transmitted infections in, 324
skin diseases in, 708
major depressive disorders, 610–611
See also mental disorders
cost-effectiveness methods and results, 613–619, 614–618t
epidemiology and burden, 610–611
interventions, 611
natural history and course, 610
policy and service implications, 619–621
public support for cost-effective intervention package, 621–622, 622t
malaria
ACT and, 421, 424
affordability and scaling up, 425
anemia and, 417–418
artemisinin to treat, 111, 1288
See also artemisinin combination therapy (ACT)
benefit-cost ratios, 427
burden of, 414–418, 414f, 415t
causes and diagnosis of, 413–414
cerebral malaria and congenital neurological disorders, 414, 935b
chemoprophylaxis, 420
civil engineering and, 422
costs and cost-effectiveness of interventions, 418–427, 422–427
switching first-line drugs, 423–424, 424f, 424t
defects due to in low- and middle-income countries, 415–416, 416t
development assistance and, 444
diagnosis and treatment of, 418–420
diagnostics for, 144
drug resistance and, 122, 414, 423–425, 424t, 1036, 1046
drug treatment of, 418–421
economic benefits of control, 425–426
economics of interventions for, 422–427
emergency medical services and, 1262
genomics and mosquitoes, 108
health education on, 422
HIV/AIDS and, 418
home repellents and insecticide use for, 422
indirect and comorbid risks, 417–418
indoor residual spraying (IRS), 421, 423, 424t, 1163
innovative approaches for, 427
interventions, 45, 418–422
combination or bundled interventions, 178
oral antimalarial treatment, 1092
oral antimalarial treatment, 1109
IPD during pregnancy and infancy, 420, 423, 424t
ITNs for prevention. See insecticide-treated nets (ITNs) for malaria prevention
larviciding and fogging, 421–422
low birthweight and, 418
Index | 1379
malaria (Continued)
macroeconomic impact of, 426
maternal conditions and, 417–418
mosquito repellents, 422
patient management, 427
policy research on, 427–428
prevention research for, 427
research and development agenda, 427–428
school-age children and, 1092, 1106
supervision and policy change, 420–421
vector control, 421–422
vertical approach to, 88
Malawi
clinical officers in, 94
diarrheal diseases in, 378
diarrheal disease treatment in, 1303
epidemiological transition in, 125
Health Technology Assessment Unit in, 125
hospital management in, 1345
occupational health in, 1134
road traffic injuries in, 740, 744
skin diseases in, 715
males. See gender differences
Mali
childhood immunization programs in, 1024
dental treatment in, 729
development assistance for health to, 245
diarrheal diseases in, 378
skin diseases in, 708
malnutrition
See also stunting, wasting, and micronutrient deficiency disorders
adolescents and, 1111
childhood illnesses and, 563, 1093
community-based interventions, 559, 561
See also community health and nutrition programs (CHNPs)
conceptual framework for causes of, 1057f
diarrhea and, 372
human capital formation and, 562
learning and developmental disabilities and, 936b
leishmaniasis and, 453
maternal undernutrition, 510
micronutrient deficiency, 1094
productivity loss and, 562–563
research and development agenda, 564–565
school-age children and, 1093
short-term hunger of children, 1094
vitamin B12 and dementia, 633
malpractice, 167, 1296
management of health services
See also integrated management of childhood illness (IMCI)
ambulatory care, 1343
capital charging and, 1345
in community and social care settings, 1343–1344
contracting for services. See outsourcing of health care services
drugs and, 1345–1346
hospitals, 1342–1343
human resources and. See medical workers
intellectual resources and, 1346
management, defined, 1340–1342
new public management, 92, 1341–1342
physical resources and, 1345
in primary care facilities, 1343
provider autonomy and, 1348
public vs. private provision, 1348
quality of care and, 1342
relationships and, 1346–1347
strategic management, 1339–1352
strategic purchasing, 1348–1349, 1349f
strengthening of, 1345
successful initiatives, 1344–1349
Management Sciences for Health, 1326
Managing Drug Supply (Quick et al.), 1326
manipulative medicine, 1282
See also complementary and alternative medicine (CAM)
marijuana. See drug dependence
mass campaigns, 88, 176
mass drug administration (MDA)
lymphatic filariasis and, 171, 439, 442, 443, 446
onchocerciasis and, 171–172, 444, 446
successful programs utilizing, 171–172
massage
back pain and, 975
manipulative medicine and, 1282
Maternal and Child Insurance Program (World Bank), 251
maternal conditions, 499–529
See also abortions; childbirth conditions
alcohol consumption and fetal alcohol syndrome, 936b
birth preparedness, 511
burden of, 508
causes and conceptual frameworks, 505
costs and cost-effectiveness of interventions, 46, 203, 513–522, 520t
diabetes and, 597
drug dependence
home-based care, 511
interventions, 508–513
iodine deficiency and, 936b
leaves learned, 522–524
malaria and, 417–418
treatment during pregnancy, 420
male involvement, 511
maternity leave from work, 221
MDGs on, 499
medical advances in, 123
nature and characteristics of, 500
neural tube defects during pregnancy, 939–940
nutritional interventions, 510
personal interventions, 510–513
policy considerations and approaches, 513
population-based interventions, 510
postpartum care, 512
primary-level care, 511–513, 515–516t
quality of evidence on, 509–510
research and development agenda, 126, 524
resource use and costs, 517
risks associated with, 1078–1079
secondary-level care, 513, 515–516t
successful programs for improving, 168
maternal mortality
abortion and, 1078
causes and conceptual frameworks, 505
emergency care and, 1263, 1278n3
family planning and, 1078–1079, 1084
health challenge of, 4b, 203, 499
levels, trends, and differentials, 505–508, 506t, 507f
reducing in low-income countries, 547b
Mauritius
combination of high blood pressure, cholesterol, and obesity in, 856
food manufacture in, 841
tax rate reduction on alcohol, 900
MDA. See mass drug administration
MDGs. See Millennium Development Goals
MDMA (ecstasy). See drug dependence
MDT. See multidrug therapy
measles
See also vaccine-preventable diseases
burden of, 395–396
elimination programs, 98–99, 168, 170, 173, 1164
predisposition for diarrheal diseases, 377
vaccine for, 98–99, 121, 395–396, 1325
vaccine gap and, 1326
Mectizan. See ivermectin
Medicaid and Oregon Health Services Commission, 263
medical workers, 1309–1322, 1310t
advice for governments on, 1320
brain drain of, 94, 95b
development assistance for health, need to target, 245
in district hospitals, 1223
experience levels of, 5b
health sector reform and, 1311
IMCI programs and, 1178, 1186
importance of, 94–96, 1344–1345
incentive pay for, 4b, 94–95, 95b, 1299, 1310–1311
incentives and motivation for, 1310–1311, 1313–1320, 1316–1317t
context and external incentives, 1314–1315
group incentives, 1318
optimal combination of compensation and incentives, 1319–1320
in practice, 1315
sustainability and, 1318–1319
typology of incentives, 1313–1314, 1314t
MDGs, human resource needs to meet, 1310
as needed resources, 1310, 1311t
numbers and types of, 1312–1313
occupational risk for HIV, hepatitis B, and hepatitis C, 1130, 1130f
paramedical personnel, 1264–1265
defined, 1262
peer review of, 1296–1297, 1299
performance-based professional recognition for, 1299–1300
performance-based remuneration for, 1299, 1348
primary care workers, 1200, 1201b
remuneration of (generally), 1310, 1315–1317
optimal combination of compensation and incentives, 1319–1320
payment methods, 1317–1318
research and development agenda, 1321
safety and effectiveness of new health professions, 1313
skills of, 1344, 1344t
surgery and, 1256
traditional healers, 1283, 1286–1287
training. See training of medical personnel
unionization of, 1315
workforce planning to meet policy goals, 1311–1312
medicinal plants, use of, 1286
See also complementary and alternative medicine (CAM)
medicine, history of, 119–120
Medicines for Malaria Venture (MMV), 140, 142, 182, 244
Mediterranean region
hemoglobinopathies in, 665, 670, 673, 674, 675
melasma, 718
meningitis, 292, 396, 486, 936b, 1334
See also vaccine-preventable diseases
mental disorders, 16, 605–606, 1343
See also specific disorders
adolescents and, 1111
anxiety disorders, 611–613
bipolar disorders, 608–610
burden of, 107, 605, 606t, 1334
cannabis and, 918
cocaine use and, 920
costs and cost-effectiveness of interventions, 47, 613–619, 621–622, 622t
estimation of population-level costs, 613–619, 615–618t
estimation of population-level effectiveness of treatments, 613, 614t
interventions, 605–606, 1343
effectiveness of, 614, 618
major depressive disorders, 610–611
mood disorders, 608–611
panic disorders, 612–613
policy and service implications, 619–621
posttraumatic stress disorder (PTSD), 605, 610
public support for cost-effective intervention package, 621–622, 622t
schizoaffective disorder, 609
schizophrenia. See schizophrenia and nonaffective psychoses (NAP)
stimulation of, 606–607, 641
suicide, 607
mental retardation
See also learning and developmental disabilities (LDDs)
Down syndrome, 941–945
iodine deficiency and, 562
Merck & Co. and ivermectin, 110, 168, 172, 440, 444
metabolic disorders, screening for, 937
metabolic syndrome, 834b
methadone. See drug dependence
Mexico
air pollution reduction in, 824b
arsenic contamination of water in, 821
cardiovascular disease in, 650
combination of high blood pressure, cholesterol, and obesity in, 853–854
dengue in, 455
diarrheal diseases in, 374, 377
drowning in, 741
fall-related injuries in, 748–749
food fortification in, 558
HIV/AIDS treatment in, 13, 358
kidney and urinary system diseases in, 703
National Crusade for Quality in Health Care in, 1299
respiratory diseases of adults in, 691
school enrollment in, 1101
skin diseases in, 708, 715
social welfare program (originally PROGRESA) and health improvements in, 24, 167–168, 169, 175, 177, 217–218, 1101
stomach cancer in, 573
universal coverage approach of, 237
VAT exemptions for medicines, physician services, and some foods, 220
water supply in, 774
micronutrient supplementation, 1058–1059
Middle East and North Africa
See also specific countries
cardiovascular disease in, 650, 656
cost of achieving, 190–191, 245
development assistance for health to, 245
diabetes in, 592, 1333
eclampsia in, 453, 462
neurological diseases in, 631
proposed guidelines for HIV/AIDS in, 347–348
skin diseases in, 714
strokes in, 634
vaccine-preventable diseases in, 399, 400, 402, 408
middle-income countries
See also specific countries
burden of disease in, 31t
cancer in, 584
causes of deaths in, 30t
financing health in, 5b, 19–20, 27–28, 236–239
See also financing
midwives, 174, 511, 545
See also childbirth conditions
migration, effect of, 104b
brain drain of medical personnel, 94, 95b, 1309–1310
Millennium Development Goals (MDGs), 24, 181–194
contracting out of health care services, effect of, 188–189
cost of achieving, 190–191, 245
detection by countries, 190–191, 191b, 192t
globally, 190
development assistance and, 185, 192–193, 234, 244, 245–246
don diarreal diseases, 384
effective interventions available for, 183–185, 184t
underuse of, 184–185
endorsement at UN Millennium Summit, 182
government and quality of policies, effect of, 185–190
government spending, mobilizing of, 192–193
health systems geared toward, 97
importance to all countries, 183
indoor air pollution and, 799, 812
on infant mortality, 7, 531, 534, 547–548
list of health-related goals, 182b
Maquette for Multisectoral Analysis, 191b
Marginal Budgeting for Bottlenecks Model, 191b
on maternal and perinatal conditions, 499
MDG Needs Assessment Model, 191b
progress report (2004), 182–183
prospects for time remaining, 183
scaling up for use of interventions, 183–185
estimating cost of, 191b
stimuli external to health sector and, 183
strengthening of core public health functions, 189–190
on TB, 290, 305
tracking progress and information needs for, 1018
on vaccine-preventable diseases, 389
on water quality, 829
mind-body medicine, 1282, 1286, 1288–1289
See also complementary and alternative medicine (CAM)
mineral fortification. See salt
minimally invasive surgery, 130–131
ministry of health, 231–232, 238
miscarriages, 939
See also abortions
MMV. See Medicines for Malaria Venture
modeling, 281
molecular epidemiology, 107–109
monogenic diseases, research priority of, 126
mood disorders, 608–611
See also mental disorders
bipolar disorders, 608–610
cost-effectiveness methods and results, 613–619, 614–618t
major depressive disorders, 610–611
policy and service implications, 619–621
public support for cost-effective intervention package, 621–622, 622t
Morocco
contraceptive use in, 1083
respiratory diseases of adults in, 691
trachoma control program in, 168, 170, 174, 178
morphine use for pain. See palliation
mortality displacement, 819
mortality rates
See also specific diseases and conditions
causes of in low- and middle-income countries, 30t
in cost-effectiveness analysis, 260
lowering of, 9–10
surveillance and, 1009
mosquitoes
See also vector control
lymphatic filariasis and, 434
malaria and. See malaria
yellow fever and, 396, 1163
motor vehicle injuries. See traffic injuries
Mount St. Helens (U.S.), 1150
Mozambique
government reform and health care delivery in, 91
leprosy in, 437
neonatal deaths in, 531
skin diseases in, 708
Multi-Country AIDS Program in Africa, 248
Multi-Country Evaluation of IMCI Effectiveness, Cost, and Impact (MCE), 1181–1184, 1183b, 1185, 1185b, 1187, 1195
multidrug therapy
See also polypill
leprosy and, 441, 442, 445
musculoskeletal determinants of health, 11b
neurological diseases
See also specific diseases and conditions
leishmaniasis, 453, 462
neurological diseases, 631
proposed guidelines for HIV/AIDS in, 347–348
research and development agenda, 977–978
risk factors for, 966, 966t
screening for, 971
surgery for, 968
symptomatic treatments for, 966–967
women and, 201, 206
Myanmar
dengue in, 454
kidney and urinary system diseases and, 697
as opium producer, 908
oral precancer and cancer in, 730
myocardial infarction. See acute myocardial infarction (AMI)
NAFTA (North American Free Trade Agreement), 1141
NAP. See schizophrenia and nonaffective psychoses
Narcotics Anonymous, 911
National Academy of Sciences (U.S.), 9
National Center for Complementary and Alternative Medicine (NCCAM), 1289
National Center for Policy Analysis (Harvard University) study of life-saving interventions, 39b
National Commission for the Protection of Human Subjects, 266, 267
National Crime Prevention Council, 760
National Evaluation of Pharmacotherapies for Opioid Dependence Project, 913
National Institute for Occupational Safety and Health (NIOSH; U.S.), 1134
National Institute of Allergy and Infectious Diseases, 114, 115
National Institutes of Health (U.S.)
on complementary and alternative medicine, 1281–1282
on COPD, 684
on eradication of infectious diseases, 1164
research fund allocation assessments, 161
national statistics office, role of, 1018
natural disasters, 1147–1162
See also disasters
NCCAM (National Center for Complementary and Alternative Medicine), 1289
neonatal conditions. See child mortality rates; childbirth conditions; perinatal conditions
neoplasms. See cancer
Nepal
arsenic contamination of water in, 821
leishmaniasis in, 452, 459
leprosy in, 437
maternal mortality in, 510
newborn care in, 535
oral health program in, 733–734
reproductive health in, 474
respiratory diseases of adults in, 691
respiratory diseases of children in, 492
sexually transmitted infections in, 323
TB in, 295
tobacco taxes in, 882
Netherlands
breast cancer in, 584
COPD and asthma in, 686
development assistance for health from, 244, 254
food manufacture to reduce fat content, 845
hospitals in, 1224–1225
transportation choices in, 840
universal coverage approach of, 237
neural tube defects during pregnancy, 939–940
neurological disorders, 627–662
Alzheimer’s disease (AD) and other dementias, 627–629
burden of, 628, 629t, 632
in children with HIV/AIDS, 935b
costs and cost-effectiveness of interventions, 47
in developing countries, 635–640, 635t, 636t, 638t, 639t
epilepsy, 629–631
See also epilepsy
learning disabilities and, 935–936b
See also learning and developmental disabilities (LDDs)
malaria and. See malaria
Parkinson’s disease, 632–633
See also Parkinson’s disease (PD) recommendations, 640
research and development agenda, 640–641
stroke, 633–635
See also stroke
burden of disease, 634
cost-effectiveness of interventions in developing countries, 638t, 639t, 640
frequency of types, prevalence, incidence rates, mortality, and disability after stroke, 633
interventions, 634–635
recommendations, 640
risk factors, 633–634
neuropsychiatric diseases
research and development agenda, 109
technological advances and, 131
new product development. See research and development
new public management, 92, 1341–1342
New Zealand
capital charging and management of physical resources in, 1345
combination of high blood pressure, cholesterol, and obesity in, 855, 859
fluoridation of water in, 725
interpersonal violence in, 765
suicide prevention for youth in, 1121
universal coverage approach of, 237
newborns. See child mortality rates; perinatal conditions
disorders of. See congenital and developmental disorders
NGOs. See nongovernmental organizations
Nicaragua
community-based programs in, 1066, 1067
injury surveillance system of, 168
interpersonal violence in, 760, 766
kidney and urinary system diseases in, 702
occupational health risks in, 1136b
performance-based remuneration for health workers in, 1299
pesticide poisoning prevention measures in, 1139
nicotine. See tobacco use and control
Niger
doctor visits for sick children in, 89
IMCI program in, 1187
Nigeria
hemoglobinopathies in, 664
IMCI program in, 1180
insecticide-treated nets (ITNs) for malaria prevention in, 217
lymphatic filariasis in, 439
malaria in, 426
neonatal deaths in, 531
neurological disorders in, 628
polio in, 254b, 1168
refugee populations and surveillance, 1008
nonaffective psychoses and schizophrenia.
See schizophrenia and nonaffective psychoses (NAP)
noncommunicable diseases, 15–16
See also specific diseases and conditions
burden of, 105, 1331
cost-effective interventions for, 53
increase in, 4b, 6
research priorities for, 115–116, 132
nonfilarial lymphoderna, 709
nongovernmental organizations (NGOs)
contracting out of medical services to, 93–94, 96b, 188
mental disorders and, 620–621
performance-based contracts with, 252–253, 252b, 1299
sanitation and, 782
North American Free Trade Agreement (NAFTA), 1141
nurses
See also medical workers
need for, 94
as primary care providers, 620
nutrition
adolescents and, 1116
breastfeeding supplementation, 555, 557b
combination of high blood pressure, cholesterol, and obesity and, 856
community-based health and nutrition programs. See community health and nutrition programs (CHNPs)
costs and cost-effectiveness of interventions, 46, 559–561, 560t, 844–846, 845t
dental caries. See dental caries
development assistance and, 248b
diabetes and, 593
diarrheal diseases and, 376
diet contributing to CVD, diabetes, and related conditions, 27, 633–634, 649, 652, 659, 699, 700, 833–836
diet fortification, 218, 254, 558, 842, 940–941
dental caries. See dental caries
folic acid. See folic acid
food manufacture and. See food manufacture
food subsidies, 212–216, 555, 842
genetically modified crops and, 131–132
global school feeding campaign, 1098b
HIV/AIDS and, 352–353
improvements from agricultural productivity, 190, 220
infants and, 555–556
lifestyle and, 835–836
micronutrient supplementation, 1058–1059
pregnant women, 510
sales tax exemptions on healthy foods and medicines, 220
school programs. See school health programs
 supplementary feeding, 1059
taxes on unhealthy foods, 219–220

obesity
aggregate costs of, 846
chronic diseases and, 833–835
in combination with high blood pressure and cholesterol, 851–868
See also cardiovascular disease (CVD)
diabetes and, 593
food taxes to discourage, 219–220
interventions to reduce, 857–858, 863
low birthweight and, 121
musculoskeletal disorders and, 966
risk factor for cancer, 574
in school-age children, 1094
surveillance data on, 1009

obsessive-compulsive disorders, 612
See also anxiety disorders
obstetric care. See childbirth conditions; maternal conditions
occupational health, 1127–1145
access to health care, 1133
back pain risks, 1136–1137
capacity building and, 1134–1135
causes of conditions in developing world, 1127–1128
company health and wellness programs, 838, 838b
control of nonoccupational exposures, 1133
costs and cost-effectiveness of interventions, 1135–1139
disease and injury research, 1143
economic aspects of intervention, 1135–1139
fiscal policies to promote, 220–221
global burden of disease from occupational health risks, 1128–1131
hearing loss and, 958
helminth infections and, 470
implementation, 1139–1142
implications for health system development, 1141–1142
improving working conditions for, 1131–1133
incidence rates of nonfatal injuries, 1139f
individual interventions, 1133
informal workforce and, 1127
international interventions for, 1131
interventions, 1131–1135
research and development agenda, 1142
lessons learned, 1139–1140
migrant workforce and, 1127–1128
preventive measures, 1135
protective equipment research, 1143
research and development agenda, 1142–1143
risks posed by exposure to asbestos and smoking, 1128, 1128t
silicosis risks, 1137, 1138b
smoking bans, 876
state or government interventions for, 1131–1132
surveillance and reporting of, 1133, 1143
technology and, 1143
workplace-based interventions, 1132–1133
occupational lung diseases, 689–690, 689f, 1128, 1128t
See also respiratory diseases of adults
silicosis, 1137, 1138b
OCP. See Onchocerciasis Control Program
OEPA. See Onchocerciasis Elimination Program for the Americas
Office of Human Research Protections (U.S.), 269n2

Onchocerciasis
burden of, 436–437
costs and cost-effectiveness of interventions, 45–46, 443–444
disease and injury research, 1143
economic aspects of intervention, 1135–1139
fiscal policies to promote, 220–221
global burden of disease from occupational health risks, 1128–1131
hearing loss and, 958
helminth infections and, 470
implementation, 1139–1142
implications for health system development, 1141–1142
improving working conditions for, 1131–1133
incidence rates of nonfatal injuries, 1139f
individual interventions, 1133
informal workforce and, 1127
international interventions for, 1131
interventions, 1131–1135
research and development agenda, 1142
lessons learned, 1139–1140
migrant workforce and, 1127–1128
preventive measures, 1135
protective equipment research, 1143
research and development agenda, 1142–1143
risks posed by exposure to asbestos and smoking, 1128, 1128t
silicosis risks, 1137, 1138b
smoking bans, 876
state or government interventions for, 1131–1132
surveillance and reporting of, 1133, 1143
technology and, 1143
workplace-based interventions, 1132–1133
occupational lung diseases, 689–690, 689f, 1128, 1128t
See also respiratory diseases of adults
silicosis, 1137, 1138b
OCP. See Onchocerciasis Control Program
OEPA. See Onchocerciasis Elimination Program for the Americas
Open Society Institute, 987
opportunistic infections (OIs) and HIV/AIDS, 353–355, 355f, 1339
oral and craniofacial diseases and disorders, 723–736
chronic gingivitis, 729–730
chronic periodontitis, 729–730
cleft lip and palate, 731
common-risk-factor intervention programs, 731–732, 732t
cost-effectiveness of oral health care, 733–734, 733f
dental caries. See dental caries
developmental disorders, 731
fluorosis of teeth, 731
HIV/AIDS and, 730
oma (cancrum oris), 730–731
oral precancer and cancer, 730
periodontal diseases, 729–730
research and future actions, 732
oral precancer and cancer, 572, 730
oral rehydration therapy (ORT), 374, 378, 1059, 1180, 1303
cost-effectiveness of, 379, 383t
Oregon Health Services Commission, 263
Organisation for Economic Co-operation and Development (OECD) on development assistance for health, 243, 244
orphan drug acts, 147
osteoarthritis. See musculoskeletal disorders
osteopathic medicine, 1282, 1288
osteoporosis. See musculoskeletal disorders
out-of-school children and youth, 1098, 1121–1122
outpatient treatment
See also primary care
TB, quality of care and treatment of, 295
outreach and referral programs, 174, 1186, 1194–1195
outsourcing of health care services, 93–94, 93b, 96b, 1320, 1347–1348
quality of care, 188–189
Pacific islands. See East Asia and Pacific
Packard Foundation, 182
PAHO. See Pan American Health Organization
pain control. See palliation
Pakistan
diarrheal diseases in, 217, 372, 378
drug addiction in, 908
hemoglobinopathies in, 670
interpersonal violence in, 756
kidney and urinary system diseases in, 697, 702, 703
leprosy in, 444
neonatal deaths in, 531
polio in, 254b
refugee populations and surveillance, 1009
respiratory diseases of children in, 493
road traffic injuries in, 749b
TB in, 291
PAL. See Practical Approach to Lung Health palliation, 981–993
implementation of strategies to improve, 989–991
interventions for pain relief, 982–987
legal controls on opioid drugs, 986–987
measurement of pain, 981
morphine use, 984–985, 986f, 987b, 1333
pain in patients with cancer and AIDS, 982
research and development agenda, 991–992
resources available to countries for developing national palliative care programs, 991b
three-step analgesic ladder, 984, 984f
Pan African Initiative, 462
Pan American Health Organization (PAHO)
campaign to eliminate polio, 168
Chagas disease campaign. See Southern Cone Initiative on Chagas disease
injury surveillance system of, 1007
Regional Core Health Data Initiative of, 1019
revolving fund for drugs, 1327
Safe Water System Initiative of, 216
Panama
scabies in, 710
universal coverage approach of, 237
yellow fever in, 396–397
panic disorder, 47, 611, 612–613
Pap smear, 575
Papua New Guinea
lymphatic filariasis in, 439
malaria in, 413, 414
newborn survival rates in, 540
quality of health care in, 1293
skin diseases in, 715, 718
water supply in, 777
Paraguay
Chagas disease in, 438
out-of-school youth in, 1122
paramedical personnel, 1262, 1264–1265
parasites. See helmint infections
Parkinson's disease (PD), 632–633
burden of, 632
costs and cost-effectiveness of interventions, 47, 637, 638t
interventions, 632–633
personal intervention, 632–633
prevalence, incidence rate, and mortality, 632
recommendations, 640
technological treatment of, 131
Partnership for Child Development (PCD), 478, 1095
Partnership in Statistics for Development in the 21st Century, 1028
Pasteur, Louis, 119, 1163
patent system and drugs, 150–152
pathophysiology, 122–124
PCD. See Partnership for Child Development
PD. See Parkinson's disease
pediculosis, 708
peer education programs, 344–345, 1115
peer review in medical profession, 1296–1297, 1299
pelvic inflammatory disease, 312
penicillin
See also antibiotics, indiscriminate use of development of, 122
resistance to, 122, 1033–1034
penicillin prophylaxis for newborns with sickle cell anemia, 670, 676–677
performance-based professional recognition for providers, 1299–1300
performance-based remuneration for providers, 1299, 1348
perinatal conditions, 499–529
breastfeeding. See breastfeeding
burden of, 508
Chagas disease and, 434
costs and cost-effectiveness of interventions, 46, 513–522, 520t
complementary feeding practices and, 376
costs and cost-effectiveness of interventions, 46, 513–522, 520t
cost-effectiveness ratios, 517, 521–522
model assumptions, 525, 525t, 526t
DALYs for, 508
defined, 500
economic benefits of intervention, 522
epidemiology of, 499–508
fetal alcohol syndrome, 936b
focus conditions and their risk factors, 501–504t
interventions, 508–513, 536–537t
lessons learned, 522–524
levels, trends, and differentials of deaths, 505–508
MDGs on, 499
policy considerations and approaches, 513
research and development agenda, 524
resource use and costs, 517
retinopathy, 954–955
sexually transmitted infections of mother and, 315
tetanus and, 394
transmission of HIV/AIDS, 335–336
Index | 1385
periodontal diseases, 729–730
See also oral and craniofacial diseases and disorders

personal interventions
Alzheimer’s disease, 629
“boutique medicine” resulting from genomics, 108
combination of high blood pressure, cholesterol, and obesity,
856–860, 861t
in developed countries, 859–860
in developing countries, 860–863
CVD, 48, 856–858
defined, 59, 274b
hearing loss, 959–960
maternal conditions, 510–513
Parkinson’s disease, 632–633
population-based interventions vs., 50
stroke, 634–635
summary of, 60–69t
using measures other than $/DALY averted, 78–82t

pertussis. See diphtheria, pertussis, tetanus
Peru
collaborative improvement model in, 1298
contracting for health care services in, 189
household fuel use in, 793, 794f
IMCI program in, 1181, 1186, 1187
immunization in, 405b
maternal and child mortality in, 1225b
quality of health services in, 1225b
sexually transmitted infections in, 323
TB control program in, 168–169, 175
pesticides, 821, 822
pharmaceuticals. See drugs
pharmacogenomics, 129, 129t
Philippine National Epidemic Surveillance System, 1004, 1004t
Philippines
childbirth in, 20, 21f
community-based programs in, 1064, 1066
diarrheal diseases in, 374, 378
immunization in, 20, 21f
kidney and urinary system diseases in, 697, 702
quality of health care in, 1296
surveillance in, 1004, 1004t
universal coverage approach of, 237
volcanic eruptions in, 1150
water pollution in, 829
phobias, 612
See also anxiety disorders
physical activity interventions, 652, 835,
838, 841b, 842, 846, 847, 970,
972–973, 1112
physicians, 94
See also medical workers
pigmentary skin disorders, 708,
717–718
PLACE (Priorities for Local AIDS Control Effort), 324–325, 326
placebo controls and ethics, 268
Planet Health program, 838b
Planned Parenthood Association of South Africa, 203
pneumoconiosis. See occupational lung diseases
pneumonia and HIV/AIDS, 354
pneumonia and influenza, 484–485,
681–684, 682–683b
See also respiratory diseases of adults;
respiratory diseases of children
drug resistance and, 1033–1034, 1045
IMCI and, 1180
improved quality of treatment for children with, 1303
Poland
cardiovascular disease in, 649, 844b
food price policies in, 219
tobacco-related legislation in, 168
policy instruments
See also legislation
defined, 59
ensuring use of resources for greatest effect, 97–98
polio
burden of, 395
elimination, goal of, 121, 168, 172, 1164,
1170–1173
costs of, 1171–1173, 1172t
IDA credit buy-downs for, 253, 254b
vaccine for, 172, 395, 406, 1164, 1171,
1325, 1326
See also vaccine-preventable diseases
pollution. See air and water pollution;
environmental risk factors; indoor air pollution
polypill
cost-effectiveness analysis of, 275, 598
preventing CVD, 598, 860–861, 863t
pooling. See risk pooling
population-based interventions
alcohol use and control, 896–899, 897t
Alzheimer’s disease, 628–629
combination of high blood pressure, cholesterol, and obesity,
855–856, 859
CVD and, 47–48
defined, 59, 274b
hearing loss, 959
maternal conditions, 510
personal interventions vs., 50
research, 109
summary of, 70–77t
surgery, 1248–1249
using measures other than $/DALY averted, 83–85t
population growth as concern, 104b,
1075–1076, 1086
posttraumatic stress disorder (PTSD), 605,
610, 621
See also anxiety disorders
Poverty Reduction Strategy Papers (PRSPs), 235–236
poverty reduction support credits (PRSCs),
248, 250–251
Practical Approach to Lung Health (PAL),
295, 691
pregnancy. See abortions; family planning;
maternal conditions; prenatal care programs
prehospital care, 1264–1271
premature births. See childbirth conditions;
low birthweight
prenatal care programs
See also maternal conditions
community health and nutrition programs, 1058
costs and cost-effectiveness of, 203
failure of women to participate in, 184
medical advances in, 123
routine prenatal care, 511–512,
514–517
prescriptions. See drugs
prevention
See also specific diseases and conditions
prevention fatigue, 312
primary. See primary prevention
research and development in preventive medicine, 107–109
secondary. See secondary prevention
price increases to deter high-risk behaviors. See specific behavior
(e.g., tobacco use)
primary care, 1193–1209
antiretroviral therapy for HIV/AIDS
and, 1204
community-oriented, 1202, 1204
comparison of proposed basic packages of interventions, 1206–1207t
comprehensive vs. selective care,
1193–1194, 1195t
cost-effectiveness of interventions, 1199, 1199t
defined, 1193
district health system and, 1202–1203
effectiveness of, 1196–1198, 1198b
equity goals and, 1198
expenditures for, 1199–1200, 1200t
“goodness of fit” within health system, 1195–1196
health effects and, 1197
home-based care, 1204
human resources for, 1200, 1201b
management of health services and, 1343
maternal and perinatal conditions and, 511–513, 515–516
nonhealth effects and, 1197–1198
nurses and, 620
outreach services of, 1194–1195
outsourcing management of, 93–94, 93b
priority setting for, 1202
private sector resources for, 1200–1202
public sector resources for, 1204
relationships with local communities, 1203
research and development agenda, 1203–1204
scaling up, 1199–1203
subsidies for, 217

primary prevention
cancer and, 572–574
CVD and, 47–48
research and development, 658
defined, 59
interpersonal violence and, 761, 763–764, 766

Priorities for Local AIDS Control Effort
(PLACE), 324–325, 326
priorities for research, 5b, 58, 103–118, 126
See also research and development
priority setting and cost-effectiveness.
See cost-effective interventions
privacy and personal genetic information, 109
private foundations, role of, 182, 253–255
See also specific foundations
private sector
district hospitals and, 1217
new product development, 146–147
primary care and, 1200–1202
priority setting and, 38
quality of care and, 1297
referral hospitals and, 1240–1241
spending on health in low-income countries, 231
producers
subsidies for, 218
taxes on, 220
product development priorities, 139–155
See also research and development
Project Accept, 360b
PRSCs. See poverty reduction support credits
PRSPs (Poverty Reduction Strategy Papers), 235–236
psychiatric disorders. See mental disorders
PTSD. See posttraumatic stress disorder

public health
history of, 120–126
surveillance. See surveillance

Public Health Schools without Walls, 1002
public knowledge. See knowledge
public-private partnerships for new product development,
147–150, 149t
pyoderma, 708, 709, 710–713, 712–713t, 718, 719t
quality-adjusted life years (QALYs), 28, 260, 261, 265
quality of health care, 1293–1307
administrative data and, 1300
assessment and assurance, 96–97
change of structural conditions and, 1296–1298
chart abstraction and, 1300
clinical vignettes and, 1301
collaborative improvement model and, 1298
cost-effectiveness of improved process, 1303–1304
definition and framework, 1293–1295, 1294f, 1295b
as determinant of cost-effectiveness, 50
in developing countries, 1295–1296
direct observation and recording of visits and, 1300
dissemination of information on quality variation, 1305–1306
on technology, 1297
district hospitals and, 1223–1224, 1224f, 1225b
drugs and vaccines, 1327
economic benefits of, 1301–1302, 1302f
economic costs of, 1302–1303
electronic medical record (EMR) and, 1300
emergency medical services, 1272
high volume of care and, 1299
internal enabling environment and, 1298
interventions affecting provider practice and, 1298–1300
legal mandates and, 1296–1297
low use due to low quality, 89–90
management of health services and, 1342, 1344
measurement of, 1300–1301
national and local clinical guidelines, 1297
organizational change and, 1297
outcomes
comparative research on outcomes and process, 1305
defined, 1294
peer review and, 1296–1297, 1299
Plan-Do-Study-Act cycle and, 1298
policy interventions to improve, 1296–1300
population-level considerations, 1295
process
comparative research on outcomes and process, 1305
defined, 1294
professional ret raining for, 1297
public-private provision of care and, 1297
referral hospitals and, 1233
research and development agenda, 1304
social macroeconomic benefits of, 1301–1302
standardized patients, use of, 1300–1301
structure, defined, 1294
TB and, 292–299
total quality management and, 1298

race
See also African Americans
dengue and, 454
sexually transmitted infections and, 316
radiation therapy for cancer, 581
raloxifene, 971, 972
rape, 758
See also interpersonal violence
referral hospitals, 1229–1243
access and equity issues, 1239
advice and support to lower levels, 1233
appropriateness of utilization of, 1238–1239
clinical services of, 1231–1233
cost-effectiveness of, 1241–1242
current balance of care and, 1237–1239
defined, 1230, 1230t
determinants of appropriate balance of referral-level care, 1236–1237
education and training, 1233–1234, 1234t
efficiency of, 1240–1242
externalities and intangible benefits of, 1235–1236
functions and benefits of, 1230–1236, 1231–1232t
health expenditure, share of, 1237–1238
HIV/AIDS and, 1239
indirect contribution to health systems, 1235
negative impacts of, 1236
private vs. public hospitals, 1240–1241
quality assurance and quality improvement, 1233
research and development agenda, 1235
surgery and, 1249–1250
unit costs of care, 1238, 1238t

Index | 1387
referral programs. See outreach and referral programs
refugee populations and surveillance, 1008–1009
registration of births, deaths, marriages, etc., 533, 1021
regulatory approach, 91–92, 92b, 96, 97, 176–177, 1131–1132
rehabilitation
defined, 59
disasters, 1153–1154
learning and developmental disabilities (LDDs), 937, 946–947
leprosy and, 441
religious customs
alternative medicine and, 630, 1281
contraceptive use and, 1080
reproductive health, 499, 1078–1079
adolescents and, 1112, 1113t, 1114–1116
sexually transmitted infections and and, 315, 316
research and development, 21–22,
107–109
See also knowledge; technological progress and health gains
adolescents and, 1122–1123
air pollution, 829–830
alcohol use and control, 902–903
alternative medicine, 1289
“appropriate science” for developing world, 109–111
“appropriate technology” for developing world, 111
“best buys,” 113t
cancer, 583–584, 1333
chronic diseases and lifestyle changes, 846
combination of high blood pressure, cholesterol, and obesity, 864–865
community health and nutrition programs, 1071–1072
contraceptives and family planning, 1087
creation of global health architecture, 117–118
CVD, 864–865
definition of research, 103
diabetes, 600
diarrheal diseases, 383–384
disaster relief, 1159–1160
drug dependence, 916
drug development, 5b, 141–143, 1335, 1336t
drug resistance, 1046
economic approaches to valuing, 157–163
methods to assess value, 161–163
economics of diagnostics, 144–146
vaccine development, 143–144
emergency medical services, 1272–1274
ethics and, 114, 265–269
expansion of global research capacity, 117
freedom of scientific inquiry for, 118
funding for, 135, 254
profits in health linked to, 160–161
genomics, 107–109
global health agendas, 106–107, 115
valuing of, 157–163
global research collaboration, 111–112, 112b, 117
health systems, 99–100, 116
hearing loss, 960
helminth infections, 479–480
HIV/AIDS, 114, 360–361, 360b
importance of, 135–136
incentives needed for, 22
indoor air pollution, 811–812
infectious diseases, 106
information systems, 1028–1029
investment in, 116–117, 244
learning and developmental disabilities, 948
lifestyle changes and chronic diseases, 846
malnutrition in childhood, 564–565
maternal and perinatal conditions, 524
medical workers, 1321
molecular epidemiology, 107–109
new product development, 139–155
development cycles, 140
development institutions, 140–141
diagnostics, 144–146
ethics and, 114, 265–269
financing and institutional arrangements, 146–150, 254
food fortification, 558
patent law and, 150–152
regulatory and liability issues for, 152–153
vaccines, 143–144
newborn health and, 524, 547
noncommunicable diseases, 115–116
nonexclusivity and, 103
nonrivalry and, 103
occupational health, 1142–1143
palliation, 991–992
patent law and, 150–152
polypill to prevent CVD. See polypill population-based research, 109
primary care, 1203–1204
priorities for research, 5b, 58, 103–118
already in global health agenda, 115
approaches to, 112–115
biomedical research, 126
emergency medical services, 1274
inherent problems in setting, 112–113
need to be in global health agenda, 115–116
participants and decision makers, role in, 114–115
product development, 139–155
promising topics for global health agenda, 116
shift of paradigm for, 117
systematic and evidence-based approach to, 113–114
push funding, 254
quality of health care, 1304
reciprocity in, 110–111
recommendations for, 116–118
referral hospitals, 1235
respiratory diseases of children, 493–494
rich country diseases vs. poor country diseases, 106, 157
schistosomiasis, 479–480
school health programs, 1105–1106
shigella vaccine, 378, 383
subsidies for, 218
surgery, 1255–1257
surveillance, 1012–1013
TB, 303–304
10:90 issue, 106, 157
traditional medicine, 1289
tropical diseases, 115, 445–446, 446t
vaccines, 407–408, 1334–1335, 1334t
water pollution, 829–830
women’s conditions, 206–207
zinc deficiency, 564
respiratory diseases of adults, 681–693
acute diseases, 45, 681–684, 682–683b, 683t, 786
avian influenza, 682b
chronic respiratory diseases, 684–689, 685f, 687t
cocaine use and, 920
COPD (chronic obstructive pulmonary disease) and asthma, 684–689, 685f
See also chronic obstructive pulmonary disease (COPD) and asthma
future research needs, 691–692
general approach to lowering risk of, 690–691
HIV/AIDS, 485, 489
occupational lung diseases, 689–690, 689f
pneumonia and influenza, 681–684, 682–683b, 683t
respiratory diseases of children, 483–497, 786
acute ear infections, 484
acute pharyngitis, 483–484
air pollution and, 820
bronchiolitis, 485
case management of, 487–489, 490t, 492–493, 494
causes and burden of, 483–485
cost-effectiveness of interventions, 489–491, 490t, 491t
HIV/AIDS and, 485, 489
hypoxemia diagnosis, 488
influenza, 485
interventions, 485–489
lessons learned on control strategies, 491–493
lower respiratory tract infections (LRIs), 484–485
newborns and resuscitation, 539–540, 539b, 545
pneumonia, 484–485
diagnosis of, 487
intramuscular antibiotics for, 488
oral treatment of, 488
treatment guidelines for, 488–489
research and development agenda, 493–494
school-age children, 1093
upper respiratory tract infections (URIs), 483–484
See also specific risks
rubella
See also vaccine-preventable diseases
congenital rubella, 935b, 937
vaccination, 406
vaccine gap and, 1326
rheumatic heart disease (RHD), 647
See also cardiovascular disease (CVD)
burden of, 650
cost-effectiveness of interventions, 653, 656, 657t, 658
epidemiological transition and, 648t
strokes and, 634
rheumatoid arthritis. See musculoskeletal disorders
rickets, 965
risk factors
See also specific risks
(e.g., cholesterol levels, obesity)
behavioral risk factor surveillance system, defined, 998
CVD and, 15, 851–868, 854t
development of concept of, 120
diabetes and, 593, 851
drug resistance and, 1031–1036
education about, 121
genomics and, 108, 108b
helminth infections and, 470
lifelong medical management of, 4b
multiple risks in combination, effect of, 108, 851–862
musculoskeletal disorders and, 966, 966t
TB and, 304
risk pooling, 226, 227–232, 236–238
river blindness. See onchocerciasis
road traffic injuries. See traffic injuries
Rockefeller Foundation
funding commitment for disease control in developing countries, 147
International AIDS Vaccine Initiative (IAVI) support from, 255b
MDGs and, 182
on sanitation and hygiene, 783
stimulating growth of public-private partnerships, 147
vaccine-preventable diseases and, 397
on yellow fever eradication, 1163
Roll Back Malaria Partnership, 182, 234, 418, 419b
Romania
cardiovascular disease in, 649, 649t
pain control in, 987b
Rotary International, 254b, 1171
rotavirus, 371, 376–377
See also diarrheal diseases
rubella
See also vaccine-preventable diseases
congenital rubella, 935b, 937
vaccination, 406
vaccine gap and, 1326
Russian Federation
cardiovascular disease in, 649, 1298
interpersonal violence in, 766
milk fluoridation in, 726
sexually transmitted infections in, 318
Rwanda
government reform and health care delivery in, 91
SAFE (surgery, antibiotics, face washing, environmental change) strategy to combat trachoma, 168, 170, 174, 178, 956
Safe Motherhood Initiative, 499, 1215
Safe Routes to School program, 840b
Safe Water System Initiative, 216
St. John’s wort,
sales tax exemptions on healthy foods and medicines, 220
Salmonella, 371
See also diarrheal diseases
salt
fluoridation, 168, 173
iodination, 168, 559
reduction in food content of, 836, 845–846, 846t
sanitation improvements, 187, 189–190, 377
See also water supply
disaster damage to, 1153
effect on burden of diseases, 786–791, 1163
epilepsy and, 631
excreta disposal, 779–784
calculation of burden of diseases, 788–789, 788t
costs of promotion, 782
diarrheal disease and, 384, 782–783, 782t
direct health benefits, 782–784
effect on burden of diseases, 786–791
effect on other disease categories, 783–784
hygiene promotion and, 786
levels of service, technologies, and costs, 779–780, 780f
policy implications, 781–782
reduction in diarrheal disease, 786–791, 786t, 787f, 789f, 790t, 790t, 791t
social benefits, 780, 780t
water supply and, 783
willingness to pay, 781
helminth infections and, 470, 472
promotion of hygiene, 784–786
calculation of burden of diseases, 788–789, 788t
costs of, 785
effect on burden of diseases, 786–791
effect on diarrheal diseases, 785
effect on respiratory infections, 785–786
evidence and, 784
reduction in diarrheal disease, 786–791, 786t, 787f, 789f, 790t, 791t
sustainability of, 784–785
subsidy for, 217
SARS (severe acute respiratory syndrome), 112b, 122, 682–683, 683t
economic effect of, 1010
surveillance and, 997, 1005
Saudi Arabia
cardiovascular disease in, 650
hemoglobinopathies in, 664
kidney and urinary system diseases and, 697
polio in, 1170
scabies, 708, 709–710, 711t, 719t
See also skin diseases
Scandinavia
See also specific countries
alcohol use and control in, 893
dental treatment in, 729
schistosomiasis
See also helminth infections
age-associated prevalence of, 470
burden of, 471
causes and characteristics of, 468
control programs, 479
cost-effective interventions for, 472, 474
epidemiology of, 468–470
kidney and urinary system diseases and, 697
mass drug administration and, 444
research and development initiatives, 479–480
water supply and, 776, 779

schizophrenia and nonaffective psychoses
(NAF), 605, 607–608
See also mental disorders
costs and cost-effectiveness of interventions, 47, 613–619, 614–618t
epidemiology and burden, 608
genomics and, 131
interventions, 608
natural history and course, 607–608
public support for cost-effective intervention package, 621–622, 622t

school health programs, 13, 1091–1108
acute respiratory infections and, 1093
burden of disease and, 1094–1095
cash-transfer programs to increase school enrollment, 1101
cognitive improvements and, 1100
cost-effectiveness of interventions, 1098–1099, 1099t
dental caries and. See dental caries designing effective programs, 1104–1105
development of programmatic approach, 1095–1097, 1096t
economic benefits of interventions, 1099–1101
FRESH framework. See Focusing Resources on Effective School Health
global school feeding campaign, 1098b
for helminth infections, 473, 474–475, 476, 1092, 1094, 1095f
HIV/AIDS and, 1092–1093, 1093f, 1105
improved school attendance, benefits of, 1100–1101
infectious disease and, 1092–1093
insurance program, 187
interventions, 1095–1098, 1098b, 1099t
key stakeholders in implementation, 1104, 1105t
lessons learned, 1101–1105

on lifestyle necessary for health, 837–838
malaria and, 1092, 1106
malnutrition and, 1093–1094, 1106
out-of-school children and, 1098, 1121–1122
pattern of disease as age specific, 1092, 1092f
research and development agenda, 1105–1106
sanitation, 783–784
sectoral roles in implementation, 1101–1104
policy and economic issues in defining, 1101
targeting food aid, 1106

Scientific Working Group on Malaria, 427
Scotland
pain control for cancer in, 986b
transportation in, 840

screening for diseases and conditions
breast cancer, 577–579, 578t, 579t, 580t
cancer screening, 123, 573, 574–575, 582
cervical cancer, 205, 573–577, 577t
congenital hyperthyroidism, 945–946
diabetes, 594, 598
Down syndrome, 941, 942–945, 944t
liver cancer, 574
lung cancer, 574–575
metabolic disorders, 937
musculoskeletal disorders, 971
prenatal screening, 942–946, 944t, 948
sickle cell disease, 675–677
thalassemias, 673–675

secondary prevention
cancer, 572, 574–579
defined, 59

secondhand smoke, 875–876
self-help programs for substance abusers, 911, 913
self-targeting, 216

Senegal
contracting for health care services in, 188, 1297
HIV/AIDS in, 106, 358
mortality decline in, 10
skin diseases in, 708, 715

sensory deficits. See blindness; hearing loss
sentinel surveillance, 1002, 1021

severe acute respiratory syndrome.
See SARS
sex distinguished from gender, 196
sexual health, 1087
adolescents and, 1112, 1113t,
1114–1116
sexually transmitted infections (STIs), 311–330
adolescents and, 1112
antibiotic use for, 314, 322
bacterial STIs and their sequelae, 314–315
behavioral risk factors associated with acquisition and transmission, 317
compensating behavior changes for, 317, 322
for exposure to infected sex partners, 316–317
burden of, 319–321
DALYs gained from prevention and treatment, 319–320, 319t
impact of STIs on HIV, 320–321, 321t
circumcision as possible protection against, 320, 322, 360b
cointection with sexually transmitted pathogens, 316
community-level interventions, 322–323
condom use for prevention, 312, 1080–1081
control strategies, 203, 232
scaling up of, 324–325
core groups and bridge populations, 313–314
costs and cost-effectiveness of intervention, 323–324
determinants of costs, 323–324, 324t
demographic and social risk markers, 316
drug resistance and, 314, 1036
duration of infectiousness, 317, 322
effectiveness of interventions, 321–323
epidemiology and control, 313–314
epidemiology and management (since 1993), 312–313
gonorrhea, 314
group-level interventions, 322
HIV/AIDS and, 312, 314

See also HIV/AIDS
income and inequality, 318, 318t, 319f
individual-level interventions, 322
prevention of acquisition, 322
prevention of transmission, 322
research and development agenda, 325–326
societal determinants, 318
syndromic management, 313, 325
syphilis, 314
vaccines for, 322
viral STIs and their sequelae, 315

shigella, 371, 374, 378
See also diarrheal diseases
drug resistance and, 1034–1036, 1045
vaccine development needed for, 378, 383

sick leave from work, 221

sickle cell anemia and related diseases
See also hemoglobinopathies
burden of, 667–669, 669t
costs and cost-effectiveness of interventions, 674t, 675–677, 676t
global distribution and frequency of, 665–667, 665f, 666t, 667t
interventions, 669–672, 677–678
neonatal screening and prophylaxis, 675–677
population genetics and dynamics, 664–665
**Sierra Leone**
development assistance for health to, 253
neonatal deaths in, 531
**Significant Caries (SiC) Index**
724, 724t
**Silicosis.** See occupational lung diseases
**Sindh Institute of Urology and Transplantation**
703
**Singapore**
Fit and Trim Program, 842
Kaposis sarcoma in, 730
National Healthy Lifestyle Program, 843b
road traffic injuries in, 744
transportation choices in, 839
**Single Convention on Narcotic Drugs (1961)**
986
**Skin diseases, 707–721**
See also leprosy
acne, 708
bacterial skin infections, 709, 710–713, 712–713t
Buruli ulcers, 709
current status of current community control measures in dermatology, 720
economic assessments and diseases in developing countries, 711–713t, 716–717t, 718–720, 719t
eczema or dermatitis, 708
effective therapies, 709, 709t
endemic treponematoses, 709
filarial lymphoedema, 709
fungal infections, 713–715
HIV-related, 707, 708, 709, 717
nonfilarial lymphoderma, 709
onchocerciasis and, 709
patterns at community level, 708–709
pediculosis, 708
pigmentary disorders of, 708, 717–718
prevalence of, 708
pyoderma, 708, 709, 710–713, 712–713t, 718, 719t
scabies, 708, 709–710, 711t, 719t
Tinea capitis, 714–715, 716t, 718, 719t
Tinea imbricata (Tokelau ringworm), 715, 717t
tropical ulcers, 709, 715, 717, 718
**Sleeping sickness.** See African trypanosomiasis
**Smallpox eradication, 121, 165, 168, 172, 1163, 1169–1170, 1169t, 1170t**
**Smoking.** See tobacco use and control
**Smuggling of tobacco products, 877**
**Soap subsidy, 121, 165, 168, 172**
**Smallpox eradication, 1165, 168, 172**
**social anxiety disorder, 611, 612**
See also anxiety disorders
**Social epidemiology**
research and development agenda, 109
**Social marketing**
adventures and, 1116, 1122
of contraceptives, 1081
**Social Marketing for Adolescent Sexual Health Project, 1122**
**Social security reforms, 228**
**Social anxiety disorder, 121, 165, 168, 172**
**Social epidemiology, 986**
611, 612
See also specific countries
alcohol consumption in, 898
breastfeeding in, 539
cardiovascular disease in, 649, 650, 652, 654, 655t, 656t
cost-effective interventions for, 50, 51t
neglected low-cost opportunities and high-cost interventions in, 54–57t
dengue in, 454, 455, 457
development assistance for health in, 245
diet in, 836
epilepsy in, 631
food manufacture in, 845
gynecologic promotion in, 784–785
leishmaniasis in, 455
malaria in, 414, 420
maternal and perinatal conditions in, 520t, 521t
mental disorders in, 614, 618, 619, 622
neonatal deaths in, 531
neurological diseases in, 628, 631
oral cancer in, 572
performance-based contracts with NGOs in, 253
proposed guidelines for HIV/AIDS in, 348–349
road traffic injuries in, 746
strokes in, 634, 640
syphilis in, 314
tobacco use and control in, 880
vital events registration in, 1021
women in, 195
**Southeast Asia**
See also specific countries
avian influenza in, 682b
ecstasy (MDMA) use in, 924
hemoglobinopathies in, 665, 666
mental disorders in, 620–621
rheumatic heart disease in, 647
strokes in, 633
**Southern Cone Initiative on Chagas disease, 167, 170, 177, 438**
**Spain**
drug-related deaths in, 909
malaria in, 421
Special Programme for Research and Training in Tropical Diseases (WHO), 114, 115, 145, 148t, 423, 446

spina bifida, 939–940

Sri Lanka
hemoglobinopathies in, 675
malaria in, 414, 418, 421
neonatal death reduction in, 533, 547b
prenatal care and childbirth in, 168, 169, 174
primary care in, 1202
water supply in, 774

STATCAP, 1028

statistics, use of, 121, 1021–1022
See also information systems

sterilization, 1080, 1082

stewardship, 91–92, 1122, 1346, 1348

sterilization, 1080, 1082

stem cell therapy, 130

statistics, use of, 121, 1021–1022
See also information systems

stroke, 633

strategic management of clinical services, 1339–1352

strategic purchasing, 1348–1349, 1349f

Strategies for Enhancing Access to Medicines Project, 92b

stroke, 633–635
See also cardiovascular disease (CVD); neurological disorders

acute management and secondary prevention of, 48

burden of, 634

cost-effectiveness of interventions in developing countries, 637, 639t, 640

frequency of types, prevalence, incidence rates, mortality, and disability after stroke, 633

interventions, 634–635, 635

ischemic heart disease (IHD) and, 646

personal interventions, 634–635

recommendations, 640

risk factors, 633–634

stunting, wasting, and micronutrient deficiency disorders, 551–567

adolescents and, 1111

causes and burden of, 551–554, 552t

community-based health interventions, 1068

costs and cost-effectiveness of interventions, 559–561, 560t

DALYs lost due to in children under age five, 552, 553t
defaths due to in children under age five, 552, 552t

economic benefits of interventions, 562–563

interventions, 555–559

iodine deficiency, 554, 558–559

iron deficiency, 553–554, 558

lessons learned, 563–564

research and development agenda, 564–565

school-age children and, 1093, 1093f

vitamin A deficiency, 553, 556–558

zinc deficiency, 554, 559

Sub-Saharan Africa
See also specific countries

African trypanosomiasis control in, 454, 456

breastfeeding in, 539

cardiobvascular disease in, 647, 649, 650, 654, 655t, 656t

contraceptive use in, 1076, 1080

cost-effective interventions for, 50, 52t

neglected low-cost opportunities and high-cost interventions in, 54–57t

diabetes in, 1333

diarrheal diseases in, 373

drug treatment in, 1346

epilepsy in, 631

guinea worm eradication in, 167, 169, 176

hemoglobinopathies in, 664, 665, 678

HIV/AIDS in, 106, 1070–1071

hospital-acquired diseases in, 1224

hospitals in, 1221b

indoor air pollution in, 803

influenza in, 684

interpersonal violence in, 757

iron deficiency in, 553–554

leishmaniasis in, 455

malaria in, 413, 414, 415, 417–418, 421, 423, 426, 935b

maternal and perinatal conditions in, 520t, 521t, 522

measles in, 396

mental disorders in, 614, 618, 619, 621–622

neonatal deaths in, 531, 533

neurological diseases in, 631

oma (Cancrum Oris) in, 730–731

poisonings in, 747–748

proposed guidelines for HIV/AIDS in, 349

provider autonomy in, 1348

school health programs in, 1101

skin diseases in, 707, 709

smallpox in, 1163

strokes in, 634

syphilis in, 314

TB in, 302

tobacco use and control in, 880

tsete flies in, 454

vaccine-preventable diseases in, 395, 397, 399, 400, 402, 408

vaccines and drugs, access to, 1346

zinc deficiency in, 554

subsidies for health and health-related products, 212–218, 212t, 213–214t

consumer subsidies, 212–218

diet, 843

food subsidies for young children, 555

producer subsidies, 218

substance abuse. See alcohol use and control; drug dependence

Sudan

African trypanosomiasis in, 456, 460

guinea worm eradication in, 169

leishmaniasis in, 453, 459

polio in, 1170–1171

refugee populations and surveillance, 1009

suicide, 16, 607, 758
See also interpersonal violence

adolescents and, 1111, 1121

costs and cost-effectiveness of interventions, 48

sulfadoxine-pyrimethamine, 45, 92

resistance to, 1032, 1036

sulfonamides, 122

surgery, 1245–1259

burden of surgical conditions, 1245–1248, 1247t

by condition and region, 1248t

methods of, 1246

for cancer, 580–581, 584

for cardiovascular disease, 651, 654, 658, 857–858

cataract surgery, 956

cases of surgical conditions, 1245–1248

community clinics and, 1249, 1253–1255, 1253t, 1254t, 1256f

coordinated model system for, 1251

costs and cost-effectiveness of interventions, 49–50, 1251–1255, 1256, 1257b

cost assumptions, 1253t

method for estimating costs and DALYs, 1252

at district hospitals, 5b, 27, 1249, 1253–1255, 1253t, 1254t, 1256f
for epilepsy, 631, 637
for hearing improvement, 959
high volume of care and quality of, 1299
hip replacement surgery, 973
human resources and, 1256
interventions, 1248–1251
for kidney disease, 701–702
knee replacement surgery, 973
for kidney disease, 701–702
minimally invasive, 130–131
for musculoskeletal disorders, 968
for Parkinson’s disease, 632–633, 637
for musculoskeletal disorders, 968
occupational health, 1133, 1143
as part of national public health systems, 1000
passive surveillance, defined, 998, 1021
population-based surveys used in, 1002
principles and uses of, 999, 999t, 1021
SARS and, 1005
sentinel surveillance, 1002, 1021
strategies for, 1002–1005
syndromic surveillance, defined, 998
as tool to improve public health, 1001–1002
training for, 117
SWaps (finance instruments), 234–235
Sweden
development assistance for health from, 244
diabetes and lifestyle changes in, 593
fluoridation programs in, 729
oral health programs in, 729, 733
fluoridation programs in, 729
oral health and education program defined, 998
oral health and education program defined, 998
oral health and education program defined, 998
oral health programs in, 729
oral precancer and cancer in, 730
oral health and education program defined, 998
oral health programs in, 729
oral precancer and cancer in, 730
Switzerland
iodine fortification program in, 554
salt fluoridation in, 725–726
synovial fluid replacement, 973
syphilis. See sexually transmitted infections (STIs)
T. vaginalis, 315
tacit knowledge, 110
Taiwan
arsenic contamination of water in, 821
strokes in, 633
universal coverage approach of, 237
tamoxifen, 574, 580
Tanzania
adolescents in, 1116
African trypanosomiasis in, 458
community-based programs in, 1066, 1068
deworming programs in, 478
DOTS development in, 111
drug shops, regulation in, 92b
HIV/AIDS in, 320, 331, 352
hospitals in, 1218
IMCI program in, 1181–1183, 1183b, 1184, 1184f, 1185b, 1186, 1187
kidney and urinary system diseases in, 702
leprosy in, 437
lymphatic filariasis in, 440
malaria in, 421, 425
malnutrition in, 1068
management of health care in, 1345, 1348
mental disorders in, 620
Multi-Country Evaluation of IMCI Effectiveness, Cost, and Impact (MCE) in, 1181–1183, 1183b
oral health and education program in, 726
primary care in, 1343, 1348
regulation of health care in, 1296
road traffic injuries in, 749b
sexually transmitted infections in, 320, 322
skin diseases in, 708, 720
strokes in, 633
training of medical staff on acute respiratory infections of children in, 1297
vital events registration in, 1021
water supply in, 773
Tanzania Essential Health Intervention Program (TEHIP), 1024, 1026–1027, 1026b, 1202, 1208n2
targeting of interventions. See specific diseases and conditions
taxation
on alcohol, 218, 893, 895t
consumer taxes, 218–220, 219b
discouraging high-risk behaviors by, 177, 213–215t
on drugs, 1327
as method of revenue collection, 227, 229
producer taxes, 220
promoting health policies, 213–215t, 218–220
sales tax exemptions on healthy foods and medicines, 220
on tobacco, 177, 218, 874–875, 875f, 879f, 882
on unhealthy foods, 219–220
TDR. See Special Programme for Research and Training in Tropical Diseases
technological progress and health gains, 10, 119–137
See also genomics
“appropriate technology” for developing world, 111
array technology, 128
community health and nutrition programs and, 1063
cost-effective interventions and, 53 in developing countries, 133
dissemination of information on, 1297
high-technology hospital practice, 125, 1223, 1226
history of 20th century for science, technology, and medicine, 120–126
immunization technologies, 1335
information and communication technologies (ICT), 1022
newborn care, 547
occupational health and, 1143
potential of information technology, 117
product development priorities, 139–155
potential of information technology, 117
product development priorities, 139–155
vaccine technologies, 1334
teach. See dental caries; oral and craniofacial diseases and disorders
TEHIP. See Tanzania Essential Health Intervention Program
television watching, 835, 838b
terrorism, 104b
attacks as disasters, 1161n1
biological, 107, 998, 1008
tertiary hospitals. See referral hospitals
tetanus. See diphtheria, pertussis, tetanus
Thailand
avian influenza in, 682b, 1005–1006
child mortality in, 1068
community-based programs in, 1059f,
1065, 1066, 1067
condom program in, 167, 170, 176
dengue in, 452, 455, 457, 459, 461
development assistance and health policy, 248b
drug dependence in, 916
epilepsy in, 630
fall-related injuries in, 748–749
hemoglobinopathies in, 668, 670, 673,
674–675
HIV/AIDS in, 13, 106, 167, 348b, 352
incentive pay to doctors in, 95, 95b
Kaposi’s sarcoma in, 730
kidney and urinary system diseases in,
697, 702, 703
medical workers in, 1315
milk fluoridation in, 726
nutrition investment in, 248b
occupational health in, 1132
oral and craniofacial diseases and disorders in, 723
road traffic injuries in, 744
sexual risk behaviors in, 312
sexually transmitted infections in, 323
skin diseases in, 708
tobacco taxes in, 882
vaccine-preventable diseases in, 406
water pollution in, 829
Thalassemia International Federation, 678
thalassemias, 127f
See also hemoglobinopathies
bone marrow transplantation, 675
burden of, 667–669
clinical features of, 664
control and treatment, 669–672
cost and effectiveness of diagnosis and management, 673–675, 674t, 675t
global distribution and frequency of,
665–666, 666f, 666t, 667f
options for control and management of,
677
population genetics and dynamics,
664–665
screening and counseling, 673–675
Tinea capitis, 714–715, 716t, 718, 719t
See also skin diseases
Tinea imbricata (Tokelau ringworm),
715, 717t
See also skin diseases
tobacco-related deaths, 15f, 120, 869,
870–871, 871t, 872f, 878–880,
879f, 882
tobacco use and control, 869–885
adolescents and, 1111, 1116
advertising restrictions, 876
bans on smoking in public places,
875–876
cancer and, 573, 833, 871–872
cardiovascular disease and, 647, 652,
659, 833
cessation, 870, 872–873, 873f, 876–877
chronic diseases and, 833
cleft lip and palate and, 731
comprehensive control programs, 881
COPD and, 688, 690, 691–692
costs and cost-effectiveness of interventions, 49, 877–880, 878t,
880t, 881t
deaths. See tobacco-related deaths
diabetes and, 597
health consequences of smoking,
870–873, 871t
interventions
government interventions, 873–874
reducing demand for tobacco, 874–877
reducing noncommunicable disease, 4b, 27
reducing supply of tobacco, 877
kidney disease and, 699, 700
musculoskeletal disorders and, 966
nicotine addiction, 873–874
nicotine replacement therapies,
876–877, 878
oral precancer and cancer and, 730
periodontal disease and, 729
price increases and, 878, 879, 882, 1116
respiratory diseases of adults, 685
smoking trends, 869–870, 870t
smuggling of tobacco products, 877
strokes and, 633, 634
taxation to discourage use, 177, 218,
874–875, 875f, 879f, 882
vision loss and, 954
warnings about, 168, 876
workers’ risk for asbestos and smoking exposure, 1128, 1128t
Togo, malaria in, 421
total quality management in health care, 1298
tourism
dengue and, 455
leishmaniasis and, 453
malaria and, 426
tax rate reduction on alcohol in Mauritius and, 900
trachoma
control program, 168, 170, 174, 178,
956–957
sanitation, prevention by, 784
water supply and, 779
Trade-Related Aspects of Intellectual Property Rights. See TRIPS
(Agreement on Trade-Related Aspects of Intellectual Property Rights)
traditional medicine. See complementary and alternative medicine (CAM)
traffic injuries, 16
adolescents and, 1111
alcohol consumption as cause of, 893, 894t
bicycle helmet legislation and enforcement, 747
burden of, 107
causes of, 739, 739t
costs and cost-effectiveness of interventions, 48
economic burden of, 737, 739
implementation of prevention and control strategies, 748–749, 749b
interventions, 742–744, 742t
motorcycle helmet legislation and enforcement, 747
risk factors for, 739–740
safer roads and, 743–744
speed and safety regulations, 745–746, 746t
speed bumps, 746–747, 747t
training of medical personnel
alternative medicine and, 1286, 1287
changes needed in medical education for global perspective, 134–135
for childbirth and newborn care, 545
community workers, 1063
continuing skill development, 1023
district hospitals' role in, 1215–1216
epidemiologists, 1002
for hospital emergency workers, 1271, 1273b
nurses, 94
for occupational health, 1134–1135, 1142
professional retraining to improve quality of care, 1297
for surgery, 1256–1257
for surveillance purposes, 117
traditional healers, 1286

transplant surgery, 130, 131

transportation
See also traffic injuries
automobile use, 839, 843
costs of unreliable systems, 187
for emergency medical services, 1264, 1267–1271
See also ambulances
intersectoral action for improvements in, 189
policy and environmental design, 839–840
walking and bicycle use, 839–840, 840b, 843–844

trauma care. See emergency medical services

Trichomonas vaginalis, 315

Trinidad and Tobago
health service agency reform in, 93, 1318–1319

TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights), 150–152, 351, 1324
tropical diseases, 433–466
See also specific types
burden of, 436–438, 454–456
characteristics and transmission, 433–436, 451–454, 454t

DALY estimates for, 437–438, 438t
interventions and effectiveness of, 45–46, 438–442, 460–463
kidney disease and, 697
management and control strategies of, 457–458, 463t
research needs and priorities, 115, 445–446, 446t
skin diseases, 709
See also skin diseases
tropical ulcers, 709, 715, 717, 718
See also skin diseases
tsetse flies, 453, 456, 458, 462, 464
tubal ligation, 1080
tuberculosis (TB), 289–309
alternative approaches to diagnosis and treatment, 294–295
burden and trends, 291–292
averted and avertable burden, 302, 302f, 303f
children and, 293
complementary strategies, 304
cost-effectiveness of interventions, 40–43, 295–297, 296f, 297t, 301–303, 301b
managing endemic TB, 297–299, 298f
managing TB outbreaks, 299–301, 300f
cost per case prevented, 297–299
cost per death prevented and DALY gained, 299
deaths due to in low- and middle-income countries, 290–291
cost per death prevented and DALY gained, 299
development assistance and, 244
diagnostics development for, 144, 145, 145t
DOTs strategy for treatment. See directly observed therapy short course (DOTS)
drug resistance and, 294, 304–305, 1036, 1045–1046
drugs for, 304, 1326
economic benefits of interventions, 302–303
HIV/AIDS and, 291, 292–293, 294, 301, 302, 304–305
impact and targets, 304
infection, disease, and death, 290–291
integrated management of, 295
interventions, 292–294
kidney and urinary system diseases and, 697
latent infection, treatment of, 292–293
MDGs and, 290, 305

outpatient and community-based treatment, 295
private sector treatment, 295
quality of care and treatment of, 27, 292–299
research and development agenda, 303–304
risk factors, 304
service delivery, 304
silicosis and, 689
successful programs in controlling, 94–95, 168–169, 174, 175
targeting poor in allocation of health resources to fight, 5b
tobacco use and, 289, 304
vaccination, 292, 304
See also vaccine-preventable diseases

Turkey
ambulances in, 1268
condom program in, 216
epithelioma in, 630
kidney and urinary system diseases in, 698, 702, 703
leishmaniasis in, 459
mental disorders in, 621
universal coverage approach of, 237
typhoid, 775t, 776t, 777, 778

Uganda
African trypanosomiasis in, 454, 456, 460
Ebola in, 1006
government reform and health care delivery in, 91, 247, 1315
HIV/AIDS in, 13, 106, 320, 348b, 354, 358
Hospice Uganda, 990
IMCI program in, 1181, 1185b, 1186, 1187
interpersonal violence in, 756, 757, 763
malaria in, 418, 421
medical workers in, 94, 1312
primary care and removal of fees for health services in, 97b
road traffic injuries in, 749b
sexually transmitted infections in, 312, 320
training of medical personnel in, 94
water supply in, 773

U.K. National Institute for Clinical Excellence, 1297

UNAIDS. See United Nations Programme on HIV/AIDS

UNESCO (United Nations Education, Scientific, and Cultural Organization), 1095

UNICEF. See United Nations Children's Fund
unintentional injuries, 737–735
burden of, 737, 738f, 738t
burn-related injuries
indoor fires and, 797–799
interventions, 743t, 744–745
risk factors for, 741
causes of, 739–741, 739t
costs, cost-effectiveness, and economic benefits of interventions, 745–748
driving injuries. See traffic injuries drowning
interventions, 743t, 745
risk factors for, 741
economic burden of, 737, 739
fall-related injuries
interventions, 743t, 744, 748–749
risk factors for, 740–741
future challenges for, 750
implementation of prevention and control strategies, 748–749, 749b
interventions, 742–743t, 742–745
occupational injuries, 1130, 1143
See also occupational health poisonings
childproof paraffin containers, 747–748
interventions, 743t, 744
risk factors for, 740
research and development agenda, 749–750
United Kingdom
air pollution causing deaths in, 819
alternative medicine in, 1285
capital charging and management of physical resources in, 1345
cigarette smoking in, 872–873, 873f, 875, 876, 881
class differences in morbidity and mortality, 124
COPD and asthma in, 686
dental treatment in, 729
development assistance for health from, 244
epilepsy in, 630
fluoridation programs in, 725, 726
Health and Safety Executive, 1135
hemoglobinopathies in, 668
heroin use in, 908, 911
high-technology hospital practice in, 125
homeopathic products, use in, 1282
hospital throughput in, 125, 130
hospitals in, 1224
International Finance Facility (IFF) proposal by, 234
London tax on cars driven into, 839
milk fluoridation in, 726
neonatal deaths in, 533
organizational structure of health systems in, 92
Public Health Act (1848), 120
skin diseases in, 714
strokes in, 633
universal coverage approach of, 237
United Nations
development assistance for health from, 244
International Conference on Population and Development (1994), 196
Millennium Development Goals. See Millennium Development Goals (MDGs)
Millennium Summit (2001), 182
United Nations Children's Fund (UNICEF)
Alma Ata Declaration. See Alma Ata Declaration on Primary Health Care (1978)
Child-Friendly Schools framework of, 1095–1096
on development assistance for health, 243
on diarrheal diseases, 374, 378
on drug procurement, 1326
guinea worm control program, 167
IMCI program. See integrated management of childhood illness (IMCI)
“marginal budgeting for bottlenecks” tool of, 541
on nutrition and child survival, 1057, 1057f, 1070
on soldiers under age of 18, 1111
on vaccine management by countries, 1329
on vaccine-preventable diseases, 394
vaccines from, 1327
on water supply, 773–774
United Nations Development Programme, 247, 811, 1095
United Nations Education, Scientific, and Cultural Organization (UNESCO), 1095
United Nations Foundation, 254b
United Nations Industrial Development Organization, 825b, 1328
United Nations Population Fund, 243, 1095
United Nations Programme on HIV/AIDS (UNAIDS), 182, 244, 245, 332, 333, 335, 347, 989
United States
air pollution in, 828, 829
alternative medicine in, 1282, 1283, 1287
arsenic contamination of water in, 821
cardiovascular disease in, 647, 650, 656, 658
cigarette smoking in, 875, 876, 881
cleft lip and palate in, 731
cocaine use in, 920
combination of high blood pressure, cholesterol, and obesity in, 859
COPD and asthma in, 686
dengue in, 455
development assistance for health from, 244, 254
diabetes in, 593, 598
diarrheal diseases in, 377
drug development and approval process, 153
See also U.S. Food and Drug Administration
ecstasy (MDMA) use in, 924
failure of “war on cancer” in, 112
fluoridation programs in, 725, 726, 729
food fortification in, 558, 842
hemoglobinopathies in, 664, 670, 675, 676
heroin use in, 908
HIV/AIDS in, 354
homeopathic products, use in, 1282
illicit drug use in, 908, 911
interpersonal violence in, 764, 765, 766
iodine fortification program in, 554
kidney and urinary system diseases in, 695–696, 698–699, 701, 702
occupational lung diseases in, 690
Occupational Safety and Health Act (1970), 1134
oral and craniofacial diseases and disorders in, 723
oral health programs in, 726, 729, 733
periodontal disease in, 730
preterm birth in, 947
primary care in, 1197
sexual risk behaviors in, 312
smallpox eradication efforts of, 1170, 1170t
urbanization
air pollution and, 819–820
lifestyle and, 840, 841b
urinary system diseases. See kidney and urinary system diseases
Uruguay
Chagas disease in, 436, 438, 442
U.S. Agency for International Development, 1297
U.S. Agency of Healthcare Research and Quality, 1297
U.S. Centers for Disease Control and Prevention
on cost of drug resistance, 1037
on drinking water quality, 216
free software for information from, 1022
guinea worm control program, 167
on measles elimination, 1164
surveillance systems of, 1000
training of epidemiologists, 1002
on violence, 755, 760
U.S. Department of Health and Human Services, 346
U.S. Environmental Protection Agency, 828
U.S. Food and Drug Administration, 141–142, 152–153, 268, 841, 1287, 1327
U.S. President's Emergency Plan for AIDS Relief, 332, 1333
U.S. Public Health Service Panel on cost-effectiveness, 262
user fees, 19, 97b, 187, 227, 1330

Vaccine Fund, 397, 491, 492
vaccine-preventable diseases, 389–411
See also vaccines; specific diseases and conditions
burden of, 394, 397
DALYs lost from, 397, 399t
deaths averted and avertable burden, 398t
causes and epidemiology of, 389–397, 390–393t
Expanded Program on Immunization. See Expanded Program on Immunization (EPI)
financial sustainability of immunization programs, 406–407
inequities in access to vaccines (vaccine gap), 1326
influenza, 684, 690, 692
research and development agenda, 407–408, 1334–1335, 1334t
respiratory diseases of children, 485–487
vaccines, 1323–1337
See also vaccine-preventable diseases; specific diseases
childhood diseases, 44–45
respiratory diseases, 485–487, 491–492
community health and nutrition programs, 1059
cost-effectiveness analysis of, 44, 276–277b
costs and cost-effectiveness of programs existing programs, 397–400, 400t
improving programs, 407
increasing coverage for traditional EPI, 401–402, 401f, 404b, 404b, 405b
new antigens, 402–406, 403t
distribution and storage, 1328–1329
economics of discovery and development, 143–144
financing of, 1331, 1332t
future challenges for, 1331–1334
immunization technologies, 1335
inequities in access to (vaccine gap), 1326
management of, 1329
policies on, 1324
procurement of, 1327
quality assurance of, 1327
research and development agenda, 407–408, 1334–1335, 1334t
selection of, 1325–1326
successful programs of, 172–173
WHO prequalification process for, 1327–1328
value of a statistical life (VSL), 8, 9, 280
value of information (VOI), 161–163, 162b
valvulitis, 647
See also rheumatic heart disease
vasectomy, 1080

vector control
African trypanosomiasis and, 458, 462–463
Chagas disease and, 438, 442
dengue and, 457, 461
leishmaniasis and, 458, 462
lymphatic filariasis and, 439–440
malaria and, 421–422
onchocerciasis and, 440
Venezuela
Chagas disease in, 438
dengue in, 455
food fortification in, 558
verbal autopsies, 1021
vertical approach to health systems, 88, 174
development assistance and, 234
management of health services and, 1346–1347
primary care and, 1194
Viagra, 1327
Viagra, 1328–1329

Vietnam
avian influenza in, 682–683b
cervical cancer screening in, 205
cholera vaccine in, 377
contraception, access to, 1086
dengue in, 452, 454, 457
diarrheal diseases in, 377
health care reform in, 247
malaria in, 418, 420, 421, 425
sexually transmitted infections in, 323
silicosis prevention measures in, 1139

TB in, 295
traditional medicine in, 1285

Vigisus project in Brazil, 1021

violence
See also interpersonal violence
adolescents and, 1111
costs and cost-effectiveness of interventions, 48

Violence against Women Act (U.S 1994), 764

viruses, control of, 122
See also specific type of virus

vision loss. See blindness

vital events registration, 1021

neonatal death information from, 533

vitamin A deficiency
blindness due to, 553
childhood illness and mortality associated with, 553
costs and cost-effectiveness of interventions, 561
diarrheal diseases and, 376
IMCI and, 1180
interventions, 556–558
lessons learned, 563, 565
mass drug administration and, 444
pregnant women and, 510
school-age children and, 1094

vitamin B12 deficiency, 627

vitamin D supplementation, 967, 971–972

VOI. See value of information

volcanic eruptions, 1150

voluntary counseling and testing (VCT) for HIV/AIDS, 332, 336, 344, 347, 348, 349

volunteer community-based programs, 1064

VSL. See value of a statistical life

war
burden of injuries from, 107
costs and cost-effectiveness of interventions, 48
soldiers under age of 18, 1111

Warmi Project in Bolivia, 535

wasting. See stunting, wasting, and micronutrient deficiency disorders

water supply, 771–779
calculation of burden of diseases, 788–789, 788t
classification and burden of water-related diseases, 775–776, 775t, 776t
conditions for health effect, 777–778
dental health. See dental caries
diarrheal disease and, 377, 776, 777, 777t, 786–791, 786t, 787f, 788–791, 789t, 790t, 791t
community health and nutrition programs, 1058
contraception. See contraception
cost-effectiveness of interventions,
203–206, 204–205t
disproportionately, 205–206
death in childbirth. See maternal
mortality
discrimination against as issue, 104b
diagnosis, 202–203
diabetes and, 474
HIV/AIDS and, 195, 196
indoor air pollution and, 79, 803
inequity in health services for. See gender
differences
leishmaniasis and, 455
life expectancy of, 5, 5f, 197, 201–202
malaria and, 413, 414, 417, 418, 422
distribution in international women's health
(1980–2003), 208–209
pregnancy. See maternal conditions;
natal care programs
research priorities for conditions creating
excess burden for, 206–207
risks associated with unwanted
pregnancies, 1077–1078, 1078t
sexually transmitted infections and, 315
underutilization of health services by, 197
vision impairment and, 955
workers' health. See occupational health
workplace violence, 760
See also interpersonal violence
World Bank
approach to ensure resources go to where
most needed, 97
Child Development projects, 1064, 1068
development assistance for health from,
244, 245, 247
development assistance for health
needs, 245, 246
drug procurement, 1326
economic growth for 2000–15, 183
excreta disposal, 779, 782
International Development Association
(IDA) grants and credits, 243,
244, 254b
International Development Group, 251
on MDGs financial requirements, 190
on pain control, 1333
polio eradication efforts and, 254b
Poverty Reduction Strategy Papers
(PRSPs), 235–236
sector adjustment loans from, 251
on skin diseases, 709
on surveillance, 1000
on user fees, 227
on water supply, 773
World Bank Development Indicators, 379
World Conference on Education for All
(1990), 1095
World Development Report 1993: Investing
in Health (World Bank), 13–14, 28,
251, 271, 1026b, 1180, 1194, 1197
World Development Report 2004: Making
Services Work for Poor People
(World Bank), 171, 179n2
World Food Program, 352
World Health Organization (WHO)
See also names of programs starting with
"WHO"
Ad Hoc Committee on Research Relating
to Future Intervention Options, 106,
111, 113, 114
on adolescent burden of disease, 1110
on African trypanosomiasis, 451, 453,
454, 456, 458, 459, 462
on air pollution, 817
on alcohol-use disorders, 902
Alma Ata Declaration. See Alma Ata
Declaration on Primary Health Care
(1978)
on antimicrobial supplements in animal
feed, 1041
on artesinin derivatives, 1046
on asthma, 688
on blindness in childhood, 957
burden of disease estimates of, 279
on cancer, 572
on cardiovascular disease, 650
on cataract surgery, 1258b
on Chagas disease, 436, 438
Choosing Interventions That Are
Cost-Effective initiative of, 860
Commission on Macroeconomics and
Health. See Commission on
Macroeconomics and Health
on contraceptive use, 1080
on COPD, 684
on cost-effective analyses, 261
on data collection, 1020
on defluoridation of water, 731
on dengue, 451, 452, 454, 455, 457, 461
on development assistance for health, 243
on diabetes, 592
on diarrheal diseases, 375, 378
on diphtheria, 394

water supply (Continued)
direct health effects, 775–779, 775t
disaster damage to, 1153, 1156
effect on other disease categories,
778–779, 778t
epidemiological questions and problems,
776–777
excreta disposal and, 384, 783
helminth infections and, 470
hygiene promotion and, 786
levels of services and costs, 771–773, 772f
pollution. See air and water pollution
purification subsidy programs, 216
quality of, 216, 771, 774
quantity of, 772
reasonable access to, 187, 772
time-saving benefit, 773–775
WaterAid, 782
weak health systems, challenge of, 99, 1340
weight. See low birthweight; obesity
Weil, Andrew, 1287
Welcome Trust, 134
WERC (Village Education Resource
Center), 782
West Africa
lymphatic filariasis in, 436
onchocerciasis in, 172, 178, 435, 437,
440, 443
yellow fever in, 396–397
Western Pacific
diarrheal diseases in, 373
neonatal deaths in, 533
rheumatic heart disease in, 647
What Works Working Group, 117, 165
WHO. See World Health Organization
WHO Alliance for the Global Elimination
of Trachoma, 957
WHO Global Network of Collaborating
Centers in Occupational Health,
1134, 1140
WHO Global Strategy for Containment of
Antimicrobial Resistance, 1043
WHO-ILO Joint Effort on Occupational
Health and Safety in Africa, 1134
WHO Priority Medicines Project, 1335
WHO-UNICEF Effective Cold Store
Management Initiative, 1329
willingness-to-pay valuation, 280
women
See also gender differences
abortion. See abortions
African trypanosomiasis and, 456
burden of disease and, 196, 197–199,
199t, 200t
cancer and, 203, 205, 570
on MDGs financial requirements, 190
on polio eradication efforts, 254b
Poverty Reduction Strategy Papers
(PRSPs), 235–236
sector adjustment loans from, 251
on skin diseases, 709
on surveillance, 1000
on user fees, 227
on water supply, 773
World Bank Development Indicators, 379
World Conference on Education for All
(1990), 1095
World Development Report 1993: Investing
in Health (World Bank), 13–14, 28,
251, 271, 1026b, 1180, 1194, 1197
World Development Report 2004: Making
Services Work for Poor People
(World Bank), 171, 179n2
World Food Program, 352
World Health Organization (WHO)
See also names of programs starting with
"WHO"
Ad Hoc Committee on Research Relating
to Future Intervention Options, 106,
111, 113, 114
on adolescent burden of disease, 1110
on African trypanosomiasis, 451, 453,
454, 456, 458, 459, 462
on air pollution, 817
on alcohol-use disorders, 902
Alma Ata Declaration. See Alma Ata
Declaration on Primary Health Care
(1978)
on antimicrobial supplements in animal
feed, 1041
on artesinin derivatives, 1046
on asthma, 688
on blindness in childhood, 957
burden of disease estimates of, 279
on cancer, 572
on cardiovascular disease, 650
on cataract surgery, 1258b
on Chagas disease, 436, 438
Choosing Interventions That Are
Cost-Effective initiative of, 860
Commission on Macroeconomics and
Health. See Commission on
Macroeconomics and Health
on contraceptive use, 1080
on COPD, 684
on cost-effective analyses, 261
on data collection, 1020
on defluoridation of water, 731
on dengue, 451, 452, 454, 455, 457, 461
on development assistance for health, 243
on diabetes, 592
on diarrheal diseases, 375, 378
on diphtheria, 394

1398 | Index
on drug accessibility, 1323, 1333, 1345–1346
drug approval process and, 153, 1327–1328
on drug research priorities, 1335
on epilepsy, 631
on eradication of infectious diseases, 1174
Expanded Program on Immunization. See Expanded Program on Immunization (EPI)
Framework Convention on Tobacco Control, 573, 882
on gender differences, 196
Global Health Initiative of, 1095
guidelines for national drug policies, 1324–1325
guinea worm control program, 167
on hearing loss from excessive noise, 959
on hemoglobinopathies, 665, 672
on HIV/AIDS, 332, 346, 355, 1333
on drug research priorities, 1335
on homeopathy, 1286, 1287
human reproduction and tropical disease research programs, 106
ILO-WHO Joint Committee on Occupational Health, 1131
IMCI program. See integrated management of childhood illness (IMCI)
on influenza, 684
on interpersonal violence, 755, 756, 766
on kidney and urinary system diseases, 697, 702, 703, 704
on leishmaniasis, 451, 454, 455
on leprosy, 437, 444
on lymphatic filariasis, 436, 439
on malaria, 88, 414–415, 1046, 1163
on measles, 395
on mental disorders, 613, 619–620, 1343
Model List of Essential Drugs of, 1324–1325
on mortality by risk factors, 11b
mother–baby package of interventions of, 514
multidrug therapy developed by, 441
on musculoskeletal disorders, 963
on neonatal deaths, 531–532, 539
on neurological disorders, 627
on newborn care, 535–536
on occupational health risks, 1128, 1129, 1130, 1140
on onchocerciasis, 437
on oral and craniofacial diseases and disorders, 723–724
oral health and education program of, 726, 731–732, 734
on oral rehydration therapy, 378
on palliative care and pain relief, 989–991, 990b
on polio eradication, 121, 1164, 1171
prequalification of drugs and vaccines by, 1327–1328
Project Focus: Ensuring Immunization Safety, 1132
Regional Office in Africa and integrated disease population surveillance, 1178
on respiratory diseases of adults, 691
on respiratory diseases of children, 488–489, 493–494
on salt intake, 836
on sexually transmitted infections, 319
on skin diseases, 707
smallpox eradication efforts of, 168, 1163–1164
on sugar intake, 836
on surveillance, 1000, 1007, 1009, 1011, 1042
on syphilis, 314
on TB, 36b, 289
“3 x 5” program of, 1333
training of epidemiologists, 1002
on Trichomonas vaginalis, 315
on unintentional injuries, 737, 741, 742
on user fees, 1330
on vaccine-preventable diseases, 394, 401, 1324
on vaccines, 1324, 1325t, 1327
on violence, 765, 766
on water pollution, 829
WHO-ILO Joint Effort on Occupational Health and Safety in Africa, 1134
on yellow fever, 397
World Health Organization-International Union against Tuberculosis and Lung Disease (WHO–IUATLD) Global Project, 1043
World Health Report 2000, 1313
World Medical Association. See Declaration of Helsinki
World Report on Violence and Health (2002), 765, 766
World Summit for Children (1990), 558, 559
World Trade Organization (WTO) Agreement on Agriculture, 220
Agreement on Technical Barriers to Trade, 220
TRIPS and, 150–152
worms. See guinea worm eradication; helminth infections
years of life lost, 28
yellow fever
control of, 1163
vaccine for, 121, 396–397, 1324, 1325
See also vaccine-preventable diseases
Yemen
onchocerciasis in, 436, 957
colio in, 1170
young adults. See adolescents and young adults
youth violence, 763–764, 765
Yugoslavia, malaria in, 421
Zambia
African trypanosomiasis in, 458, 460
dent treatment in, 729
health service agency reform in, 93, 1315, 1318
hospitals in, 1343
IMCI program in, 1187
Kaposi’s sarcoma in, 730
malnutrition in, 421
primary care in, 1343
quality of health care in, 1344
sexually transmitted infections in, 323
Zanzibar
African trypanosomiasis in, 458, 460
Zimbabwe
African trypanosomiasis in, 458, 460
cervical cancer screening in, 205, 576, 577t
community-based programs in, 1066, 1067
contracting for health care services in, 189, 1347–1348
excreta disposal in, 782
hygiene promotion in, 785
infant mortality in, 1068
Kaposi’s sarcoma in, 730
malnutrition in, 1068
oral health and education program in, 726
primary health care nurses in, 1313
quality of health care in, 1297
regulation of health care in, 1296
road traffic injuries in, 749b
sexually transmitted infections in, 318
taxes on alcohol in, 218
traditional medicine in, 1283, 1284
zinc deficiency
costs and cost-effectiveness of interventions, 561, 565
diarrheal disease and, 378
human capital formation and, 562
IMCI and, 1180
mortality and, 554
research on, 564